U.S. patent application number 13/005121 was filed with the patent office on 2011-07-07 for methods of diagnosing alzheimer's disease.
Invention is credited to Christian Baumann, Helen Byers, Abdul Hye, Richard Joubert, Stefan Kienle, Karsten Kuhn, Simon Lovestone, Stephen Lynham, Petra Prefot, Thorsten Prinz, Juergen Schaefer, Malcolm Ward, Jules Westbrook.
Application Number | 20110165146 13/005121 |
Document ID | / |
Family ID | 33397455 |
Filed Date | 2011-07-07 |
United States Patent
Application |
20110165146 |
Kind Code |
A1 |
Westbrook; Jules ; et
al. |
July 7, 2011 |
METHODS OF DIAGNOSING ALZHEIMER'S DISEASE
Abstract
Methods and compositions relating to Alzheimer's disease are
provided. Specifically, proteins that are differentially expressed
in the Alzheimer's disease state relative to their expression in
the normal state are provided. Proteins associated with Alzheimer's
disease are identified and described. Methods of diagnosis of
Alzheimer's disease using the differentially expressed proteins are
also provided, as are methods for the identification and
therapeutic use of compounds for the prevention and treatment of
Alzheimer's disease.
Inventors: |
Westbrook; Jules; (Dublin,
IE) ; Byers; Helen; (Cobham Surrey, GB) ;
Ward; Malcolm; (London, GB) ; Lovestone; Simon;
(London Greater London, GB) ; Hye; Abdul; (London,
GB) ; Lynham; Stephen; (London, GB) ; Joubert;
Richard; (Niedernhausen, DE) ; Prefot; Petra;
(Wiesbaden, DE) ; Kuhn; Karsten; (Hofheim, DE)
; Baumann; Christian; (Offenbad, DE) ; Schaefer;
Juergen; (Lauterbach, DE) ; Prinz; Thorsten;
(Hofheim, DE) ; Kienle; Stefan; (Frankfurt,
DE) |
Family ID: |
33397455 |
Appl. No.: |
13/005121 |
Filed: |
January 12, 2011 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
11664076 |
Oct 16, 2007 |
7897361 |
|
|
PCT/GB05/03756 |
Sep 29, 2005 |
|
|
|
13005121 |
|
|
|
|
Current U.S.
Class: |
424/130.1 ;
435/7.1; 436/86 |
Current CPC
Class: |
G01N 2800/2821 20130101;
A61P 25/28 20180101; G01N 2800/52 20130101; G01N 33/6896
20130101 |
Class at
Publication: |
424/130.1 ;
435/7.1; 436/86 |
International
Class: |
A61K 39/395 20060101
A61K039/395; G01N 33/53 20060101 G01N033/53; G01N 33/00 20060101
G01N033/00; A61P 25/28 20060101 A61P025/28 |
Foreign Application Data
Date |
Code |
Application Number |
Sep 29, 2004 |
GB |
0421639.6 |
Claims
1. A method of diagnosing Alzheimer's disease in a subject, the
method comprising detecting at least one differentially expressed
protein in a tissue sample or body fluid sample from said
subject.
2. A method according to claim 1, wherein the nature or degree of
the Alzheimer's disease is determined.
3. A method according to claim 2, wherein the progression of the
Alzheimer's disease over time is determined.
4. A method of determining the nature or degree of Alzheimer's
disease in a human or animal subject, the method comprising: (a)
establishing a paradigm in which at least one protein is
differentially expressed in relevant tissue or body fluid sample
from, or representative of, subjects having differential levels of
Alzheimer's disease; (b) obtaining a sample of the tissue or body
fluid from the subject; (c) determining the presence, absence or
degree of expression of the differentially expressed protein or
proteins in the sample; and (d) relating the determination to the
nature or degree of the Alzheimer's disease by reference to a
previous correlation between such a determination and clinical
information.
5. The method of claim 4, wherein the severity of the Alzheimer's
disease is determined.
6. The method of claim 4 wherein the duration of the Alzheimer's
disease is determined.
7. A method according to claim 4, wherein the tissue or body fluid
sample is a urine, blood, plasma, serum, saliva or cerebro-spinal
fluid sample.
8. A method according to claim 4 wherein an increase in the
expression of said protein is detected compared to that of a
control subject.
9. A method according to claim 4 wherein a decrease in the
expression of said protein is detected compared to that of a
control subject.
10. A method according to claim 1 wherein the differentially
expressed protein is detected using an antibody specific to said
protein, by detecting in the sample an autoantibody specific to
said protein, or by mass spectrometry.
11. A method according to claim 1 wherein the differentially
expressed protein is detected using 2D gel electrophoresis.
12. A method according to claim 10 wherein the sample is
immobilised on a solid support.
13. A method according to claim 1 which comprises detecting more
than one differentially expressed protein.
14. A method according to claim 13 which comprises detecting four
or more differentially expressed proteins.
15. A method according to claim 13, whereby a pattern of said
differentially expressed proteins in a tissue sample or body fluid
sample of an individual with Alzheimer's disease is used to predict
the most appropriate and effective therapy to alleviate the
Alzheimer's disease and to monitor the success of that
treatment.
16. A method according to claim 1 wherein said at least one
differentially expressed protein is a protein shown in FIG. 6, FIG.
7, FIG. 8 or FIG. 12.
17. A method according to claim 5 wherein at least one of said
differentially expressed proteins is Ig lambda chain C region with
accession no P01834 found in Spot 177 as shown in FIG. 6.
18. A method according to claim 6 wherein at least one of said
differentially expressed proteins is the serum albumin precursor
isoform found in Spot 165 as shown in FIG. 6.
19. A method according to claim 16 wherein said at least one
differentially expressed proteins is one of the following proteins
shown in FIG. 6, FIG. 7, FIG. 8 or FIG. 12 or a fragment thereof:
apolipoprotein A-IV precursor, apolipoprotein C-III precursor,
transthyretin, galectin 7, complement C4 precursor, complement
factor H, S100 calcium binding protein or ceruloplasmin, histone
2B, Ig lambda chain C region, fibrinogen gamma chain precursor,
inter-alpha-trypsin heavy chain H4 precursor, complement C3
precursor, clusterin precursor, gamma or beta actin, haptoglobin
precursor or the serum albumin precursor isoform found in spot ID
no 2, 14, 15, 123, 165, 176 or 184 of FIG. 6.
20. A method according to claim 19, wherein said fragment
comprises; residues 270-309 of apolipoprotein A-IV; resides
680-1446-1744 of complement C4; or wherein said fragment is an
N-terminal fragment of apolipoprotein A-IV which migrates as a 28
kD fragment in SDS-PAGE.
21. A method according to claim 19 wherein said at least one
differentially expressed proteins is one of the following proteins
shown in FIG. 6, FIG. 7 or FIG. 12 or a fragment thereof:
alpha-2-macroglobulin, Ig alpha-1 chain C, apolipoprotein A-IV,
complement factor H or serum albumin precursor found in Spot 2 of
FIG. 6
22. The method of claim 1 which further comprises determining an
effective therapy for treating the Alzheimer's disease.
23. A method of treatment by the use of an agent that will restore
the expression of one or more differentially expressed proteins in
the Alzheimer's disease state to that found in the normal state in
order to prevent the development or progression of Alzheimer's
disease.
24. A method of screening an agent to determine its usefulness in
treating Alzheimer's disease, the method comprising: (a) obtaining
a sample of relevant tissue or body fluid taken from, or
representative of, a subject having Alzheimer's disease symptoms,
who or which has been treated with the agent being screened; (b)
determining the presence, absence or degree of expression of a
differentially expressed protein or proteins in the tissue from, or
representative of, the treated subject; and, (c) selecting or
rejecting the agent according to the extent to which it changes the
expression, activity or amount of the differentially expressed
protein or proteins in the treated subject having Alzheimer's
disease symptoms.
25. A method according to claim 24, which method further comprises,
prior to step (a), the step of establishing a paradigm in which at
least one protein is differentially expressed in relevant tissue or
body fluid from, or representative of, subjects having Alzheimer's
disease symptoms and normal subjects.
26. The method of claim 24, wherein the agent is selected if it
converts the expression of the differentially expressed protein or
proteins towards that of a normal subject.
27. The method of claim 24, wherein the agent is selected if it
converts the expression of the protein or proteins to that of the
normal subject.
28. A method of screening an agent to determine its usefulness in
treating Alzheimer's disease, the method comprising: (a) obtaining
over time samples of relevant tissue or body fluid taken from, or
representative of, a subject having Alzheimer's disease symptoms,
who or which has been treated with the agent being screened; (b)
determining the presence, absence or degree of expression of a
differentially expressed protein or proteins in said samples; and,
(c) determining whether the agent affects the change over time in
the expression of the differentially expression protein in the
treated subject having Alzheimer's disease symptoms.
29. A method according to claim 28, which method further comprises,
prior to step (a), the step of establishing a paradigm in which at
least one protein is differentially expressed in relevant tissue or
body fluid from, or representative of, subjects having Alzheimer's
disease symptoms and normal subjects; and establishing that
expression of said differentially expressed protein diverges over
time in subjects having Alzheimer's disease symptoms and normal
subjects.
30. The method of claim 25, wherein the subjects having
differential levels of protein expression comprise: (a) normal
subjects and subjects having Alzheimer's disease symptoms; and, (b)
subjects having Alzheimer's disease which have not been treated
with the agent and subjects Alzheimer's disease symptoms which have
been treated with the agent.
31. The method of claim 30, wherein the differential levels of
protein expression are not observed in normal subjects who have and
have not been treated with the agent.
32. The method of claim 25, wherein the subjects having Alzheimer's
disease symptoms are human subjects with Alzheimer's disease.
33. The method of claim 25, wherein the subjects having Alzheimer's
disease symptoms are mutant amyloid precursor protein (APP)
transgenic mice, presenilin-1 (PS-1) transgenic mice, double
transgenic APP/PS-1 transgenic mice and/or glycogen synthase kinase
transgenic mice, and the normal subjects are wild-type mice.
34. The method of claim 33, wherein the tissue or body fluid
samples are brain tissue samples.
35. The method of claim 33, wherein the tissue or body fluid
samples are urine, blood, plasma, serum, saliva or cerebro-spinal
fluid samples.
36. The method of claim 4, wherein the paradigm is established
using two-dimensional gel electrophoresis carried out on the
relevant tissue or a protein-containing extract thereof.
37. The method of claim 4, wherein the paradigm is established
using SELDI analysis of the relevant tissue or a protein-containing
extract thereof.
38. The method of claim 24, wherein the differentially expressed
protein or proteins comprise at least one of the proteins shown in
FIG. 6, FIG. 7, FIG. 8 and FIG. 12, or a rodent equivalent
thereof.
39. A method according to claim 38 wherein at least one of said
differentially expressed proteins is one of the following proteins
shown in FIG. 6, FIG. 7, FIG. 8 or FIG. 12 or a fragment thereof:
apolipoprotein A-IV precursor, apolipoprotein C-III precursor,
transthyretin, galectin 7, complement C4 precursor, histone 2B, Ig
lambda chain C region, fibrinogen gamma chain precursor, complement
factor H, inter-alpha-trypsin heavy chain H4 precursor, complement
C3 precursor, clusterin precursor, gamma or beta actin, haptoglobin
precursor or the serum albumin precursor isoform found in spot ID
no 2, 14, 15, 123, 165, 176 or 184 of FIG. 6, or a rodent
equivalent thereof.
40. A method according to claim 40, wherein said fragment comprises
amino acid residues 270-309 of apolipoprotein A-IV; or residues
1446-1744 of complement C4; or a rodent equivalent thereof.
41. A method according to claim 39 wherein at least one of said
differentially expressed proteins is one of the following proteins
shown in FIG. 6, FIG. 7 or FIG. 12, or a fragment thereof:
alpha-2-macroglobulin, Ig alpha-1 chain C apolipoprotein A-IV,
complement factor H or serum albumin precursor found in Spot 2 of
FIG. 6; or a rodent equivalent thereof.
42. A method of making a pharmaceutical composition which comprises
having identified an agent using the method of claim 24, the
further step of manufacturing the agent and formulating it with an
acceptable carrier to provide the pharmaceutical composition.
43. A method of identifying a protein which is differentially
expressed in relevant tissue or body fluid sample from subjects
with Alzheimer's disease and normal subjects, comprising: i)
immobilising a tissue sample or body fluid sample or
protein-containing extract thereof on a solid support ii) analysing
the immobilised proteins by surface enhanced laser desorption time
of flight mass spectroscopy iii) comparing the spectra obtained to
detect differences in protein expression between Alzheimer's
subjects and normal subjects.
44. The method of claim 43, wherein the tissue or body fluid
samples are blood, serum or cerebro-spinal fluid samples.
45. The method of claim 43, further comprising the step of
isolating a differentially expressed protein identified in the
method.
46. The method of claim 45, further comprising the step of
characterising the isolated protein.
47. The method of claim 28, wherein the agent is selected if it
prevents or slows the change over time in the expression of the
differentially expressed protein.
Description
FIELD OF THE INVENTION
[0001] The present invention relates to methods and compositions
relating to Alzheimer's disease. Specifically, the present
invention identifies and describes proteins that are differentially
expressed in the Alzheimer's disease state relative to their
expression in the normal state and, in particular, identifies and
describes proteins associated with Alzheimer's disease. Further,
the present invention provides methods of diagnosis of Alzheimer's
disease using the differentially expressed proteins. Still further,
the present invention provides methods for the identification and
therapeutic use of compounds for the prevention and treatment of
Alzheimer's disease.
BACKGROUND OF THE INVENTION
[0002] Dementia is one of the major public health problems of the
elderly, and in our ageing populations the increasing numbers of
patients with dementia is imposing a major financial burden on
health systems around the world. More than half of the patients
with dementia have Alzheimer's disease (AD). The prevalence and
incidence of AD have been shown to increase exponentially. The
prevalence for AD in Europe is 0.3% for ages 60-69 years, 3.2% for
ages 70-79 years, and 10.8% for ages 80-89 years (Rocca, Hofman et
al. 1991). The survival time after the onset of AD is approximately
from 5 to 12 years (Friedland 1993).
[0003] Alzheimer's disease (AD), the most common cause of dementia
in older individuals, is a debilitating neurodegenerative disease
for which there is currently no cure. It destroys neurons in parts
of the brain, chiefly the hippocampus, which is a region involved
in coding memories. Alzheimer's disease gives rise to an
irreversible progressive loss of cognitive functions and of
functional autonomy. The earliest signs of AD may be mistaken for
simple forgetfulness, but in those who are eventually diagnosed
with the disease, these initial signs inexorably progress to more
severe symptoms of mental deterioration. While the time it takes
for AD to develop will vary from person to person, advanced signs
include severe memory impairment, confusion, language disturbances,
personality and behaviour changes, and impaired judgement. Persons
with AD may become non-communicative and hostile. As the disease
ends its course in profound dementia, patients are unable to care
for themselves and often require institutionalisation or
professional care in the home setting. While some patients may live
for years after being diagnosed with AD, the average life
expectancy after diagnosis is eight years.
[0004] In the past, AD could only be definitively diagnosed by
brain biopsy or upon autopsy after a patient died. These methods,
which demonstrate the presence of the characteristic plaque and
tangle lesions in the brain, are still considered the gold standard
for the pathological diagnoses of AD. However, in the clinical
setting brain biopsy is rarely performed and diagnosis depends on a
battery of neurological, psychometric and biochemical tests,
including the measurement of biochemical markers such as the ApoE
and tau proteins or the beta-amyloid peptide in cerebrospinal fluid
and blood.
[0005] Biomarkers may possibly possess the key in the next step for
diagnosing AD and other dementias. A biological marker that fulfils
the requirements for the diagnostic test for AD would have several
advantages. An ideal biological marker would be one that identifies
AD cases at a very early stage of the disease, before there is
degeneration observed in the brain imaging and neuropathological
tests. A biomarker could be the first indicator for starting
treatment as early as possible, and also very valuable in screening
the effectiveness of new therapies, particularly those that are
focussed on preventing the development of neuropathological
changes. A biological marker would also be useful in the follow-up
of the development of the disease.
[0006] Markers related to pathological characteristics of AD;
plaques and tangles (A.beta. and tau) have been the most
extensively studied. The most promising has been from studies of
CSF concentration of A.beta.(1-40), A.beta.(1-42) and tau or the
combination of both proteins in AD. Many studies have reported a
decrease in A.beta.(1-42) in CSF, while the total A.beta. protein
or A.beta.(1-40) concentration remain unchanged (Ida, Hartmann et
al. 1996; Kanai, Matsubara et al. 1998; Andreasen, Hesse et al.
1999).
SUMMARY OF THE INVENTION
[0007] Broadly, the present invention relates to methods and
compositions for the diagnosis of Alzheimer's disease. More
specifically, the present invention identifies and describes
proteins that are differentially expressed in the Alzheimer's
disease state relative to their expression in the normal state.
[0008] In a first aspect, the invention provides a method of
diagnosing Alzheimer's disease in a subject, the method comprising
detecting one or more of a differentially expressed protein
identified by the methods described herein in a tissue sample or
body fluid sample from said subject. Preferably, the method is an
in vitro method.
[0009] In all aspects, the methods of the present invention may
also be used in relation to pre-Alzheimer's stages such as mild
cognitive impairment (MCI) as well as advanced Alzheimer's
disease.
[0010] In another aspect, the present invention provides a method
of determining the nature or degree of Alzheimer's disease in a
human or animal subject, the method comprising detecting one or
more of a differentially expressed protein identified by the
methods described herein in a tissue sample or body fluid sample
from said subject. Thus, the methods of the present invention
encompass methods of monitoring the progress of Alzheimer's disease
or of disease progression from MCI to Alzheimer's disease. Also
encompassed are prognostic methods, for example prognosis of likely
progression from MCi to Alzheimer's disease, or prognosis of likely
duration or severity of Alzheimer's disease.
[0011] In a preferred embodiment the method comprises: [0012] (a)
establishing a paradigm in which at least one protein is
differentially expressed in relevant tissue or body fluid sample
from, or representative of, subjects having differential levels of
Alzheimer's disease; [0013] (b) obtaining a sample of the tissue or
body fluid sample from the subject; [0014] (c) determining the
presence, absence or degree of expression of the differentially
expressed protein or proteins in the sample; and [0015] (d)
relating the determination to the nature or degree of the
Alzheimer's disease by reference to a previous correlation between
such a determination and clinical information.
[0016] In one embodiment, the progression of the disorder may be
tracked by using the methods of the invention to determine the
severity of the disorder, e.g. global dementia severity). In
another embodiment, the duration of the disorder up to the point of
assessment may be determined using the methods of the invention.
For example, expression of an Ig lambda chain C region (see spot
177, FIG. 6) may correlate with global dementia severity.
Expression of a serum albumin precursor (see spot 165, FIG. 6) may
show a negative correlation with the duration of the disease.
[0017] This method allows the type of Alzheimer's disease of a
patient to be correlated to different types to prophylactic or
therapeutic treatment available in the art, thereby enhancing the
likely response of the patient to the therapy.
[0018] In some embodiments, more than one protein is differentially
expressed, providing a multi-protein fingerprint of the nature or
degree of the Alzheimer's disease. Preferably, at least four
proteins are differentially expressed.
[0019] Conveniently, the patient sample used in the methods of the
invention can be a tissue sample or body fluid sample such as a
blood, plasma, serum or urine sample. Use of body fluids such as
those listed is preferred because they can be more readily obtained
from a subject. This has clear advantages in terms of cost, ease,
speed and subject wellbeing. Blood, blood products such as plasma,
and urine are particularly preferred.
[0020] The step of detecting the differentially expressed protein
may be preceded by a depletion step to remove the most abundant
proteins from the sample, as described below.
[0021] Preferably, at least one of the differentially expressed
proteins is a protein shown in FIG. 6, FIG. 7 or FIG. 12. In
preferred embodiments, the differentially expressed protein is
apolipoprotein A-IV precursor, apolipoprotein C-III precursor,
transthyretin, galectin 7, complement C4 precursor,
alpha-2-macroglobulin precursor, Ig alpha-1 chain C, histone 2B, Ig
lambda chain C region, fibrinogen gamma chain precursor, complement
factor H, inter-alpha-trypsin heavy chain H4 precursor, complement
C3 precursor, clusterin precursor, gamma or beta actin, haptoglobin
precursor or the serum albumin precursor isoform found in spot ID
no 2, 14, 15, 123, 165, 176 or 184 of FIG. 6 or fragments thereof.
Preferred fragments are a C-terminal fragment of Apo-AIV or a C4
alpha region of complement C4 precursor Lacking the anaphylatoxin
domain. For example, the fragment may comprise amino acid residues
270-309 of apolipoprotein A-IV; residues 1446-1744 of complement
C4, or may be an N-terminal fragment of apolipoprotein A-IV which
migrates as a polypeptide of 10-16 kD or a polypeptide of 28 kD in
SDS-PAGE, or a fragment of any of the proteins in FIG. 7 with a
molecular weight of 6430, 14640, 27147 or 14646 Da. Other preferred
fragments comprise the areas indicated in bold in FIGS. 9, 10, and
13 to 19.
[0022] Preferred fragments are less than 50, less than 100, less
than 150 less than 200, less than 250, less than 300, less than
350, less than 400, less than 500, less than 600, less than 700,
less then 800, less than 900, less than 1000, less than 1100, less
than 1200, less than 1300, less than 1400, less than 1500, less
than 1600, less than 1700, less than 1800, less than 1900 or less
than 2000 amino acids in length.
[0023] The expression of certain differentially expressed proteins
may be increased in subjects with Alzheimer's disease as compared
to control subjects. The expression of other differentially
expressed proteins may be decreased in subjects with Alzheimer's
disease as compared to control subjects. FIGS. 6, 8 and 12 indicate
whether the expression of the proteins disclosed therein is
increased or decreased in Alzheimer's versus control subjects. It
is thus clear from the figures whether an increase or decrease in
expression is indicative of the disease state for all the proteins
listed therein. Including the preferred proteins listed above.
[0024] Preferably, a differentially expressed protein shows a fold
difference in expression of at least 1.5, at least 1.6, at least
1.7, at least 1.8, at least 1.9, at least 2.0, at least 2.5, at
least 3, at least 3.5, at least 4, at least 5, at least 10 or more
between the level found in patients with Alzheimer's versus control
subjects.
[0025] The differentially expressed protein may be detected using
an antibody specific to that protein, for example in an ELISA assay
or Western blotting. Alternatively, the differentially expressed
protein may be detected by, amongst others, 2D gel electrophoresis
or mass spectrometry techniques including LS/MS/MS, MALDI-TOF or
SELDI-TOF. The sample may be immobilised on a solid support for
analysis.
[0026] In one embodiment, a diagnosis may be made solely on the
basis of the pattern of spots on a 2D gel prepared from a subject
sample. The pattern of spots obtained from Alzheimer's disease or
MCI subjects may be compared directly with the pattern obtained
from control subject samples, without the need for identifying
individual proteins.
[0027] In one embodiment, an antibody sandwich technique where
antibodies specific for one or more of the biomarkers is added and
the immobilised antibodies capture the biomarker protein. The
captured proteins are then detected using a second antibody that
may be directly labelled with a signal generating agent (enzyme,
fluorescent tag, radiolabel etc.) or may be detected using further
amplification (labelled secondary antibody, streptavidin/biotin
systems with enzyme, fluorophore, radiolabel etc.). Other
immunological methods may include one-dimensional or
two-dimensional gel elctrophoresis of patient samples followed by
transfer to a solid surface using techniques such as Western
blotting and subsequent detection using antibodies specific for the
AD biomarkers.
[0028] In an alternative embodiment, autoantibodies to the
biomarkers may be detected by using the Western blotting approach
described above using either samples from a patient or
representative of AD and then detecting the presence of antibodies
specific for the biomarker that are present in the blood of AD
patients but not in controls.
[0029] The method may further comprise determining an effective
therapy for treating the Alzheimer's disease.
[0030] In a further aspect, the present invention provides a method
of treatment by the use of an agent that will restore the
expression of one or more differentially expressed proteins in the
Alzheimer's disease state towards that found in the normal state in
order to prevent the development or progression of Alzheimer's
disease. Preferably, the expression of the protein is restored to
that of the normal state.
[0031] In a further aspect, the present invention provides a method
whereby the pattern of differentially expressed proteins in a
tissue sample or body fluid sample or urine of an individual with
Alzheimer's disease is used to predict the most appropriate and
effective therapy to alleviate the Alzheimer's disease.
[0032] Also provided is a method of screening an agent to determine
its usefulness in treating a Alzheimer's disease, the method
comprising: [0033] (a) obtaining a sample of relevant tissue taken
from, or representative of, a subject having Alzheimer's disease
symptoms, who or which has been treated with the agent being
screened; [0034] (b) determining the presence, absence or degree of
expression of the differentially expressed protein or proteins in
the tissue from, or representative of, the treated subject; and,
[0035] (c) selecting or rejecting the agent according to the extent
to which it changes the expression, activity or amount of the
differentially expressed protein or proteins in the treated subject
having Alzheimer's disease symptoms.
[0036] Optionally, the method may further comprise, prior to step
(a), the step of establishing a paradigm in which at least one
protein is differentially expressed in relevant tissue from, or
representative of, subjects having Alzheimer's disease symptoms and
normal subjects.
[0037] Preferably, the agent is selected if it converts the
expression of the differentially expressed protein towards that of
a normal subject. More preferably, the agent is selected if it
converts the expression of the protein or proteins to that of the
normal subject.
[0038] Also provided is a method of screening an agent to determine
its usefulness in treating Alzheimer's disease, the method
comprising: [0039] (a) obtaining over time samples of relevant
tissue or body fluid taken from, or representative of, a subject
having Alzheimer's disease symptoms, who or which has been treated
with the agent being screened; [0040] (b) determining the presence,
absence or degree of expression of a differentially expressed
protein or proteins in said samples; and, [0041] (c) determining
whether the agent affects the change over time in the expression of
the differentially expression protein in the treated subject having
Alzheimer's disease symptoms.
[0042] Optionally, the method may further comprise, prior to step
(a), the step of establishing a paradigm in which at least one
protein is differentially expressed in relevant tissue or body
fluid from, or representative of, subjects having Alzheimer's
disease symptoms and normal subjects; and/or [0043] establishing
that expression of said differentially expressed protein diverges
over time in subjects having Alzheimer's disease symptoms and
normal subjects.
[0044] Samples taken over time may be taken at intervals of weeks,
months or years. For example, samples may be taken at monthly,
two-monthly, three-monthly, four-monthly, six-monthly,
eight-monthly or twelve-monthly intervals.
[0045] A change in expression over time may be an increase or
decrease in expression, compared to the initial level of expression
in samples from the subject and/or compared to the level of
expression in samples from normal subjects. The agent is selected
if it slows or stops the change of expression over time.
[0046] In the screening methods described above, subjects having
differential levels of protein expression comprise: [0047] (a)
normal subjects and subjects having Alzheimer's disease symptoms;
and, [0048] (b) subjects having Alzheimer's disease symptoms which
have not been treated with the agent and subjects Alzheimer's
disease which have been treated with the agent.
[0049] In alternative embodiments, the subjects having differential
levels of protein expression comprise: [0050] (a) normal subjects
who have and have not been treated with the agent; and one or both
of [0051] (b) subjects having mild cognitive impairment who have
and have not been treated with the agent; and [0052] (c) subjects
having Alzheimer's disease symptoms who have and have not been
treated with the agent.
[0053] Preferably, the differential levels of protein expression
are not observed in normal subjects who have and have not been
treated with the agent.
[0054] The subjects having Alzheimer's disease symptoms are
preferably human subjects with Alzheimer's disease.
[0055] Alternatively, the subjects having Alzheimer's disease
symptoms may be an animal model such as mutant amyloid precursor
protein (APP) transgenic mice, presenilin-1 (PS-1) transgenic mice,
and/or double transgenic APP/PS-1 transgenic mice.
[0056] The tissue or body fluid samples may be, for example, brain
tissue, blood, plasma, serum, saliva or cerebro-spinal fluid
samples.
[0057] In one embodiment, the paradigm is established using
two-dimensional (2D) gel electrophoresis carried out on the
relevant tissue or a protein-containing extract thereof.
[0058] In another embodiment, the paradigm is established using
SELDI analysis of the relevant tissue or a protein-containing
extract thereof. Preferably, the tissue or extract is immobilised
on a solid support, for example a chip.
[0059] Conveniently, a depletion step may be performed prior to 2D
gel electrophoresis or SELDI analysis, to remove the most abundant
proteins from the samples and reduce background.
[0060] The method may further comprise the step of isolating a
differentially expressed protein identified in the method, and
optionally the step of characterising the isolated protein.
[0061] Preferably, at least one of the differentially expressed
proteins is a protein shown in FIG. 6, FIG. 7, FIG. 8 or FIG. 12 or
a rodent equivalent thereof. In preferred embodiments, the
differentially expressed protein is apolipoprotein A-IV precursor,
apolipoprotein C-III precursor, transthyretin, galectin 7,
complement C4 precursor, complement factor H, S100 calcium binding
protein or ceruloplasmin, inter-alpha-trypsin heavy chain H4
precursor, complement C3 precursor, clusterin precursor, gamma or
beta actin, haptoglobin precursor or fragments thereof. Preferred
fragments are a C-terminal fragment of Apo-AIV or a C4 alpha region
of complement C4 precursor lacking the anaphylatoxin domain. For
example, the fragment may comprise amino acid residues 270-309 of
apolipoprotein A-IV; residues 1446-1744 of complement C4.
[0062] Preferred fragments will comprise one or more of the
sequences highlighted in FIGS. 9, 10 and 13-19.
[0063] In a further aspect, the invention provides a method of
making a pharmaceutical composition which comprises having
identified an agent using the method described above, the further
step of manufacturing the agent and formulating it with an
acceptable carrier to provide the pharmaceutical composition.
[0064] In a further aspect, the invention provides a method of
identifying a protein which is differentially expressed in relevant
tissue or body fluid sample from subjects with mild cognitive
impairment and/or subjects with Alzheimer's disease and normal
subjects, comprising:
[0065] i) immobilising a tissue sample or body fluid sample or
protein-containing extract thereof on a solid support
[0066] ii) analysing the immobilised proteins by surface enhanced
laser desorption time of flight mass spectroscopy
[0067] iii) comparing the spectra obtained to detect differences in
protein expression between Alzheimer's subjects and normal
subjects.
[0068] Also provided is protein which is differentially expressed
in relevant tissue from, or representative of subjects having
differential levels of Alzheimer's disease symptoms and which is as
obtainable by the methods described herein or by two-dimensional
gel electrophoresis carried out on said tissue or a
protein-containing extract thereof, the method comprising: [0069]
(a) providing non-linear immobilized pH gradient (ILG) strips of
acrylamide polymer 3 mm.times.180 mm; [0070] (b) rehydrating the
IPG strips in a cassette containing 25 ml. of an aqueous solution
of urea (8M),
3-[(cholamidopropyl)dimethylammonio]-1-propanesulphonate (CHAPS, 2%
w/v), 0.5% IPG Pharmalyte and a trace of Bromophenol Blue; [0071]
(c) emptying the cassette of liquid, transferring the strips to an
electrophoretic tray fitted with humid electrode wicks, electrodes
and sample cups, covering the strips and cups with low viscosity
paraffin oil; [0072] (d) applying 200 micrograms of an aqueous
solution of dried, powdered material of the relevant body tissue in
urea (8M), CHAPS (4% w/v), Tris (40 mM), 0.5% IPG Pharmalyte and a
trace of Bromophenol Blue to the sample cups, at the cathodic end
of the IPG strips; [0073] (e) carrying out isoelectric focusing on
the gel at S1 500V step-n-hold (s/h) for 1 h; S2 500V s/h for 2 h;
S3 1000V gradient (G) for 1 h; S4 1000V s/h for 2 h; S5 8000V G for
2 h and S6 8000V s/h for a time effective to enable the proteins to
migrate in the strips to their pI-dependent final positions; [0074]
(f) equilibrating the strips within the tray with 100 ml of an
aqueous solution containing Tris-HCl (50 mM) pH 6.8, urea (6M),
glycerol (30% v/v), SDS (2% w/v) and DTT (10 mg/ml); [0075] (g)
replacing this solution by 100 ml. of an aqueous solution
containing Tris-HCl (50 mM) pH 8.8, urea (6M), glycerol (30% v/v),
SDS (2% w/v), iodoacetamide (25 mg/ml) and a trace of Bromophenol
Blue and incubating for 20 minutes; [0076] (h) providing a vertical
gradient slab gel 160.times.200.times.1.5 mm of
acrylamide/piperazine-diacrylyl cross-linker (9-16% T/2.6% C),
polymerised in the presence of TEMED (0.5% w/v), ammonium
persulphate (0.1% w/v) and sodium thiosulphate (5 mM), in Tris-HCl
(0.375M) pH 8.8 as leading buffer; [0077] (i) over-layering the gel
with sec-butanol for about 2 hours, removing the overlay and
replacing it with water; [0078] (j) cutting the IPG gel strips to a
size suitable for the second dimensional electrophoresis, removing
6 mm from the anode end and 14 mm from the cathode end; [0079] (k)
over-layering the slab gel with an aqueous solution of agarose
(0.5% w/v) and Tris-glycine-SDS (25 mM-198 mM-0.1% w/v) as leading
buffer, heated to 70.degree. C. and loading the IPG gel strips onto
the slab gel through this over-layered solution; [0080] (l) running
the second dimensional electrophoresis at a constant current of 40
mA at 8-12.degree. C. for 5 hours; and (m) washing the gel.
[0081] This invention is based, in part, on systematic search
strategies involving sensitive detection of proteins by
2D-electrophoresis. To aid the identification of differentially
expressed protein a standard marker set of proteins such as those
available from Genomic Solutions may be run on an extra lane to 2D
electrophoresis.
[0082] The examples presented below demonstrate the successful use
of the experimental paradigms of the invention to identify target
proteins associated with Alzheimer's disease.
DEFINITIONS
[0083] "Differential expression", as used herein, refers to at
least one recognisable difference in tissue or body fluid protein
expression. It may be a quantitatively measurable,
semi-quantitatively estimatable or qualitatively detectable
difference in tissue protein expression. Thus, a differentially
expressed protein (herein DEP) may be strongly expressed in tissue
in the normal state and less strongly expressed or not expressed at
all in tissue in the Alzheimer's disease state. Conversely, it may
be strongly expressed in tissue in the Alzheimer's disease state
and less strongly expressed or not expressed at all in the normal
state. Further, expression may be regarded as differential if the
protein undergoes any recognisable change between the two states
under comparison.
[0084] The term "paradigm" means a prototype example, test model or
standard.
[0085] Wherever a differentially expressible protein is used in the
screening procedure, it follows that there must have been at some
time in the past a preliminary step of establishing a paradigm by
which the differential expressibility of the protein was
pre-determined. Once the paradigm has been established, it need not
be re-established on every occasion that a screening procedure is
carried out. The term "establishing a paradigm" is to be construed
accordingly.
[0086] "Relevant tissue" means any tissue involved in brain
function, in particular tissue involved in Alzheimer's disease.
[0087] "Tissue/Body fluid . . . representative of . . . subjects"
means any tissue or body fluid in which the above-mentioned
biological change can be simulated for laboratory purposes and
includes, for example, a primary cell culture or cell line derived
ultimately from relevant tissue.
[0088] The term "subjects" includes human and animal subjects.
[0089] The treatments referred to above can comprise the
administration of one or more drugs or foodstuffs, and/or other
factors such as diet or exercise.
[0090] The differentially expressed proteins (DEPs) include
"fingerprint proteins", "target proteins" or "pathway
proteins".
[0091] The term "fingerprint protein", as used herein, means a DEP,
the expression of which can be used, alone or together with other
DEPs, to monitor or assess the condition of a patient suspected of
suffering from Alzheimer's disease. Since these proteins will
normally be used in combination, especially a combination of four
or more, they are conveniently termed "fingerprint proteins",
without prejudice to the possibility that on occasions they may be
used singly or along with only one or two other proteins for this
purpose. Such a fingerprint protein or proteins can be used, for
example, to diagnose a particular type of Alzheimer's disease and
thence to suggest a specific treatment for it.
[0092] The term "diagnosis", as used herein, includes the provision
of any information concerning the existence, non-existence or
probability of the disorder in a patient. It further includes the
provision of information concerning the type or classification of
the disorder or of symptoms which are or may be experienced in
connection with it. This may include, for example, diagnosis of the
severity of the disorder. It encompasses prognosis of the medical
course of the disorder, for example its duration, severity and the
course of progression from MCI to Alzheimer's disease.
[0093] Currently disease status is assessed by duration of disease
from inception to present (longer duration equals more severe
disease) and clinical assessment measures. These assessment
measures include clinical tests for memory and other cognitions,
clinical tests for function (abilities of daily living) and
clinical assessments of global severity. Trials of potential
therapies in AD are currently evaluated against these measures. The
FDA and other medicines approval bodies require as part of these
assessments measures of both cognition and global function. The
Global Dementia Scale is one such measure of global function. It is
assessed by rater assessment of severity including cognition and
function against a standardised set of severity criteria.
[0094] The term "target protein", as used herein, means a DEP, the
level or activity of which can be modulated by treatment to
alleviate Alzheimer's disease. Modulation of the level or activity
of the target protein in a patient may be achieved, for example, by
administering the target protein, another protein or gene which
interacts with it or an agent which counteracts or reduces it, for
example an antibody to the protein, competitive inhibitor of the
protein or an agent which acts in the process of transcription or
translation of the corresponding gene.
[0095] The term "alleviate", as used herein, in relation to
Alzheimer's disease means any form of reducing one or more
undesired symptoms or effects thereof. Any amelioration of
Alzheimer's disease of the patient falls within the term
"alleviation". Amelioration may also include slowing down the
progression of the disease.
[0096] Alternatively or additionally, the DEPs can interact with at
least one other protein or with a gene involved in the regulation
of brain function. Such other proteins are termed herein "pathway
proteins" (PPs). The term is applied to the protein with which the
DEP interacts, not to the DEP itself, although a pathway protein
can be another DEP.
[0097] By way of example, embodiments of the present invention will
now be described in more detail with reference to the accompanying
figures.
BRIEF DESCRIPTION OF THE FIGURES
[0098] FIG. 1 shows spectra for the 6430 Da peak identified by
SELDI analysis in normal (top) and Alzheimer's disease (bottom)
subjects.
[0099] FIG. 2 shows spectra for the 14640 Da peak identified by
SELDI analysis in normal (top) and Alzheimer's disease (bottom)
subjects.
[0100] FIG. 3 shows spectra for the 27147 Da peak identified by
SELDI analysis in normal (top) and Alzheimer's disease (bottom)
subjects.
[0101] FIG. 4 shows spectra for the 14646 Da peak identified by
SELDI analysis in pooled normal (top) and Alzheimer's disease
(bottom) subjects.
[0102] FIG. 5 shows a silver stained gel obtained from material
extracted from the chips used for SELDI analysis. The bands (1-6)
excised and analysed by LC/MS/MS are indicated by arrows.
[0103] FIG. 6 shows differentially expressed proteins identified by
2D gel analysis and mass spectroscopy.
[0104] FIG. 7 shows differentially expressed proteins identified by
SELDI and LC/MS/MS.
[0105] FIG. 8 shows differentially expressed proteins identified by
qPST.
[0106] FIG. 9 shows the sequence coverage (indicated in bold)
obtained for apolipoprotein A-IV (P06727) in the 14.6 kDa band
isolated on the Q10 SAX2 SELDI chip. C-terminal residues 270-396
are underlined.
[0107] FIG. 10 shows sequence coverage (indicated in bold) obtained
for Complement C4 precursor (P01028) in 2DE spot 164.
[0108] FIG. 11 shows a 2D gel obtained from the pre-depletion
analysis. The differentially expressed spots are circled.
[0109] FIG. 12 lists the differentially expressed spots identified
by the pre-depletion analysis. Column 3 gives the accession number
for the human protein, column 4 the mean normalised spot volume in
the control samples, column 6 the mean normalised spot volume in
the disease samples, column 8 the mean normalised spot volume in
the disease sample divided by that in the control sample, column 9
the significance (p-value) of the difference in spot volumes
compared by Student's t-test, column 10 the number of gels in the
control group in which the spot was detected. CV is coefficient of
variation.
[0110] FIG. 13 shows sequence coverage (indicated in bold) obtained
for alpha-2 macroglobulin (P01023) in the pre-depletion analysis.
The signal sequence is underlined.
[0111] FIG. 14 shows sequence coverage (indicated in bold) obtained
for inter-alpha trypsin inhibitor heavy chain H4 precursor (Q14624)
in the pre-depletion analysis. The signal sequence is
underlined.
[0112] FIG. 15 shows sequence coverage (indicated in bold) obtained
for complement C3 precursor (P01024) in the pre-depletion analysis.
The signal sequence is underlined.
[0113] FIG. 16 shows sequence coverage (indicated in bold) obtained
for clusterin precursor (P10909) in the pre-depletion analysis. The
signal sequence is underlined.
[0114] FIG. 17 shows sequence coverage (indicated in bold for spot
832 and bold italic for spot 652) obtained for complement C4
precursor (P01028) in the pre-depletion analysis. The signal
sequence is underlined.
[0115] FIG. 18 shows sequence coverage (indicated in bold) obtained
for gamma actin (P63261) in the pre-depletion analysis. The signal
sequence is underlined.
[0116] FIG. 19 shows sequence coverage (indicated in bold) obtained
for haptoglobin precursor (P00738) in the pre-depletion analysis.
The signal sequence is underlined.
DETAILED DESCRIPTION
[0117] Methods and compositions for the treatment of Alzheimer's
disease. Proteins termed `target proteins` and/or fingerprint
proteins are described which are differentially expressed in
Alzheimer's disease states relative to their expression in normal
states. Methods for the identification of such fingerprint and
target proteins are also described.
[0118] `Differential expression` as used herein indicates that a
protein is present at different levels in samples from normal and
diseased subjects.
[0119] Also described below are methods for prognostic and
diagnostic evaluation of Alzheimer's disease states and for the
identification of subjects exhibiting a predisposition to
Alzheimer's disease.
1. Identification of Differentially Expressed and Pathway
Proteins
[0120] In one embodiment, the present invention concerns methods
for the identification of proteins which are involved in
Alzheimer's disease. Such proteins may represent proteins which are
differentially expressed in Alzheimer's disease states relative to
their expression in normal states. Such differentially expressed
proteins may represent `target` or `fingerprint` proteins.
[0121] Methods for the identification of such proteins are
described in Section 1. Methods for the further characterisation of
such differentially expressed proteins and for their identification
as target and/or fingerprint proteins are presented below in
Section 1.1.
[0122] `Differential expression`, as used herein, refers to both
qualitative as well as quantitative differences in protein
expression. Thus a differentially expressed protein may
qualitatively have its expression activated or completely
inactivated in normal versus Alzheimer's disease state. Such a
qualitatively regulated protein will exhibit an expression pattern
within a given tissue, cell type or body fluid sample which is
detectable in either control or Alzheimer's disease subject, but
not detectable in both. Alternatively, such a qualitatively
regulated protein will exhibit an expression pattern within a given
tissue, cell type or body fluid sample, which is detectable in
either control or Alzheimer's disease subjects but not detectable
in both. `Detectable`, as used herein, refers to a protein
expression pattern, which are detectable using techniques described
herein.
[0123] Alternatively, a differentially expressed protein may have
its expression modulated, i.e. quantitatively increased or
decreased, in normal versus Alzheimer's disease states. The degree
to which expression differs in normal versus Alzheimer's disease
states need only be large enough to be visualised via standard
characterisation techniques, such as silver staining of
2D-electrophoretic gels. Other such standard characterisation
techniques by which expression differences may be visualised are
well known to those skilled in the art. These include successive
chromatographic separations of fractions and comparisons of the
peaks, capillary electrophoresis, separations using micro-channel
networks, including on a micro-chip, SELDI analysis and qPST
analysis.
[0124] Chromatographic separations can be carried out by high
performance liquid chromatography as described in Pharmacia
literature, the chromatogram being obtained in the form of a plot
of absorbance of light at 280 nm against time of separation. The
material giving incompletely resolved peaks is then
re-chromatographed and so on.
[0125] Capillary electrophoresis is a technique described in many
publications, for example in the literature "Total CE Solutions"
supplied by Beckman with their P/ACE 5000 system. The technique
depends on applying an electric potential across the sample
contained in a small capillary tube. The tube has a charged
surface, such as negatively charged silicate glass. Oppositely
charged ions (in this instance, positive ions) are attracted to the
surface and then migrate to the appropriate electrode of the same
polarity as the surface (in this instance, the cathode). In this
electroosmotic flow (EOF) of the sample, the positive ions move
fastest, followed by uncharged material and negatively charged
ions. Thus, proteins are separated essentially according to charge
on them.
[0126] Micro-channel networks function somewhat like capillaries
and can be formed by photcablation of a polymeric material. In this
technique, a UV laser is used to generate high energy light pulses
that are fired in bursts onto polymers having suitable UV
absorption characteristics, for example polyethylene terephthalate
or polycarbonate. The incident photons break chemical bonds with a
confined space, leading to a rise in internal pressure,
mini-explosions and ejection of the ablated material, leaving
behind voids which form micro-channels. The micro-channel material
achieves a separation based on EOF, as for capillary
electrophoresis. It is adaptable to micro-chip form, each chip
having its own sample injector, separation column and
electrochemical detector: see J. S. Rossier et al., 1999,
Electrophoresis 20: pages 727-731.
[0127] Surface enhanced laser desorption ionisation time of flight
mass spectrometry (SELDI-TOF-MS) combined with ProteinChip
technology can also provide a rapid and sensitive means of
profiling proteins and is used as an alternative to 2D gel
electrophoresis in a complementary fashion. The ProteinChip system
consists of aluminium chips to which protein samples can be
selectively bound on the surface chemistry of the chip (eg.
anionic, cationic, hydrophobic, hydrophilic etc). Bound proteins
are then co-crystallised with a molar excess of small
energy-absorbing molecules. The chip is then analysed by short
intense pulses of N2 320 nm UV laser with protein separation and
detection being by time of flight mass spectrometry. Spectral
profiles of each group within an experiment are compared and any
peaks of interest can be further analysed using techniques as
described below to establish the identity of the protein.
[0128] Quantitative protein sequence tag (qPST) technology may also
be used to detect differentially expressed proteins. Briefly, the
proteins in the samples for comparison are labelled with a stable
isotope tag. A different isotope is used for each sample. The
proteins are enzymatically cleaved and the labelled peptides in
each sample are quantified by mass spectrometry. In this way,
expression of equivalent proteins in the different samples can be
compared directly by comparing the intensities of their respective
isotopic peaks.
[0129] Detection of differentially expressed proteins may be
preceded by a depletion step to remove the most abundant proteins
from the sample. The large majority of the protein composition of
serum/plasma consists of just a few proteins. For example, albumin,
which is present at a concentration of 35-50 mg/ml, represents
approximately 54% of the total protein content with IgG adding
other 16%. In contrast, proteins changing in response to disease,
for example as a result of tissue leakage, may circulate at 10
ng/ml. This vast dynamic range of protein concentrations represents
a major analytical challenge and to overcome the problem, a
multiple affinity depletion column can be used to remove the most
highly abundant proteins (eg the 5, 6, 7, 8, 9 or 10 most highly
abundant proteins). This enables the detection of changes in lower
abundance ranges because more starting material can be used and
there is less interference from the highly abundant molecules. Such
a depletion strategy can be applied before any detection
method.
[0130] Differentially expressed proteins may be further described
as target proteins and/or fingerprint proteins. `Fingerprint
proteins`, as used herein, refer to a differentially expressed
protein whose expression pattern may be utilised as part of a
prognostic or diagnostic Alzheimer's disease evaluation or which,
alternatively, may be used in methods for identifying compounds
useful for the treatment of Alzheimer's disease. A fingerprint
protein may also have characteristics of a target protein or a
pathway protein.
[0131] `Target protein`, as used herein, refers to a differentially
expressed protein involved in Alzheimer's disease such that
modulation of the level or activity of the protein may act to
prevent the development of Alzheimer's disease. A target protein
may also have the characteristics of a fingerprint protein or a
pathway protein.
1.1 Characterisation of Differentially Expressed Proteins
[0132] Differentially expressed proteins, such as those identified
via the methods discussed above, may be further characterised by
using, for example, methods such as those discussed herein. Such
proteins will be referred to herein as `identified proteins`.
[0133] Analyses such as those described herein, yield information
regarding the biological function of the identified proteins. An
assessment of the biological function of the differentially
expressed proteins, in addition, will allow for their designation
as target and/or fingerprint proteins.
[0134] Specifically, any of the differentially expressed proteins
whose further characterisation indicates that a modulation of the
proteins expressed or a modulation of the proteins activity may
ameliorate Alzheimer's disease will be designated `target
proteins`, as defined above, in Section 1.
[0135] Any of the differentially expressed proteins whose
expression pattern contributes to a protein `fingerprint` profile
correlative of Alzheimer's disease, will be designated a
`fingerprint protein`. `Fingerprint profiles` will be more fully
discussed below. It should be noted that each of the target
proteins may also function as fingerprint proteins.
[0136] A variety of techniques can be utilised to further
characterise the identified proteins. First, the corresponding
nucleotide sequence of the identified protein may be obtained by
utilising standard techniques well known to those of skill in the
art, may, for example, be used to reveal homologies to one or more
known sequence motifs which may yield information regarding the
biological function of the identified protein.
[0137] Secondly, the biological function of the identified proteins
may be more directly assessed by utilising relevant in vivo and in
vitro systems. In vivo systems may include, but are not limited to,
animal systems which naturally exhibit Alzheimer's disease-like
symptoms and/or pathology, or ones which have been engineered to
exhibit such symptom and/or pathology. Further, such systems may
include systems for the further characterisation of Alzheimer's
disease, and may include, but are not limited to, naturally
occurring and transgenic animal systems.
[0138] In vitro systems may include cell lines derived from such
animals or Alzheimer's disease subjects. Animal models may be used
to generate cell lines, containing one or more cell types involved
in Alzheimer's disease, that can be used as cell culture models for
this disorder. While primary cultures derived from the transgenic
animals of the invention may be utilised, the generation of
continuous cell lines is preferred. For examples of techniques
which may be used to derive a continuous cell line from the
transgenic animals, see Small, et al., 1985, Mol. Cell. Biol. 5:
642-648.
[0139] Preferred transgenic animal models of Alzheimer's disease
include mice overexpressing glycogen synthase kinase (GSK) (see
Lucas et al (2001) EMBO J. 20, p27-39), mice overexpressing mutant
alleles of APP or PS1 and double (APP/PS1) transgenic mouse models
overexpressing mutant alleles of both APP and PS1. Double
transgenic mice resulting from a cross between a mutant APP line
Tg2576 and a mutant PS1M146L transgenic line is reported in Holcomb
et al., Nat. Med. 1998 January; 4(1):97-100).
[0140] In further characterising the biological function of the
identified proteins, the expression of these proteins may be
modulated within the in vivo and/or in vitro systems, i.e. either
overexpressed or underexpressed in, for example, transgenic animals
and/or cell lines, and its subsequent effect on the system then
assayed. Alternatively, the activity of the identified protein may
be modulated by either increasing or decreasing the level of
activity in the in vivo and/or in vitro system of interest, and its
subsequent effect then assayed.
[0141] The information obtained through such characterisations may
suggest relevant methods for the treatment of Alzheimer's disease
using the protein of interest. For example, treatment may include a
modulation of protein expression and/or protein activity.
Characterisation procedures such as those described herein may
indicate where such modulation should involve an increase or a
decrease in the expression or activity of the protein of interest.
Such methods of treatment are discussed below in Section 4.
2. Differentially Expressed Proteins
[0142] Identified proteins, which include differentially expressed
proteins such as those identified in Section 1 above, are described
herein. Specifically, the amino acid sequences of such identified
proteins are described. Further, antibodies directed against the
identified protein, and cell- and animal-based models by which the
identified proteins may be further characterised and utilised are
also discussed in this Section.
2.1 Antibodies Specific for Differentially Expressed or Pathway
Proteins
[0143] The present invention also relates to methods for the
production of antibodies capable of specifically recognising one or
more differentially expressed or pathway protein epitopes. Such
antibodies may include, but are not limited to, polyclonal
antibodies, monoclonal antibodies (mAbs), humanised or chimeric
antibodies, single chain antibodies, Fab fragments, F(ab').sub.2
fragments, fragments produced by a Fab expression library,
anti-idiotypic (anti-Id) antibodies, and epitope-binding fragments
of any of the above. Such antibodies may be utilised as part of
Alzheimer's disease treatment methods, and/or may be used as part
of diagnostic techniques whereby patients may be tested for
abnormal levels of fingerprint, target, or pathway gene proteins,
or for the presence of abnormal forms of such proteins.
[0144] For the production of antibodies to a differentially
expressed or pathway protein, various host animals may be immunised
by injection with a differentially expressed or pathway protein, or
a portion thereof. Such host animals may include, but are not
limited to, rabbits, mice and rats, to name but a few. Various
adjuvants may be used to increase the immunological response,
depending on the host species, including active substances such as
lysolecithin, Pluronic polyols, polyanions, peptides, oil
emulsions, keyhole limpet hemocyamin, dinitrophenol, and
potentially useful human adjuvant such as BCG bacille
Calmette-Fuerin) and Corynebacterium parvum.
[0145] Polyclonal antibodies are heterogeneous populations of
antibody molecules derived from the sera of animals immunised with
an antigen, such as target proteins, or an antigenic functional
derivative thereof. For the production of polyclonal antibodies,
host animals such as those described above, may be immunised by
injection with differentially expressed or pathway protein
supplemented with adjuvants as also described above.
[0146] Monoclonal antibodies, which are homogeneous populations of
antibodies to a particular antigen, may be obtained by any
technique, which provides for the production of antibody molecules
by continuous cell lines in culture. These include, but are not
limited to, the hybridoma technique of Kohler and Milstein (1975,
Nature 256; 495-497; and U.S. Pat. No. 4,376,110), the human
.beta.-cell hybridoma technique (Kosbor, et al., 1983, Immunology
Today 4: 72; Cole, et al., 1983, Proc. Natl. Acad. Sci. USA 80;
2026-2030), and the EBV-hybridoma technique (Cole, et al., 1985,
Monoclonal Antibodies and Cancer Therapy, Alan R. Liss Inc., pp.
77-96). Such antibodies may be of any immunoglobulin class
including IgG, IgM, IgE, IgA, IgD and any subclass thereof. The
hybridoma producing the mAb of this invention may be cultivated in
vitro or in vivo. Production of high titers of mAbs in vivo makes
this the presently preferred method of production.
[0147] In addition, techniques developed for the production of
`chimeric antibodies` (Morrison, et al., 1984, Proc. Natl. Acad.
Sci. 81: 6851-6855; Neuberger, et al., 1984, Nature 312: 604-608;
Takeda, et al., 1985, Nature 314: 452-454) by splicing the genes
from a mouse antibody molecule of appropriate antigen specificity
together with genes from a human antibody molecule of appropriate
biological activity can be used. A chimeric antibody is a molecule
in which different portions are derived from different animal
species, such as those having a variable region derived from a
murine in mAb and a human immunoglobulin constant region.
[0148] Alternatively, techniques described for the production of
single chain antibodies (U.S. Pat. No. 4,946,778; Bird, 1988,
Science 242: 423-426; Huston, et al., 1988, Proc. Natl. Acad. Sci.
USA 85: 5879-5883; and Ward, et al., 1989, Nature 334: 544-546) can
be adapted to produce differentially expressed or pathway
protein-single chain antibodies. Single chain antibodies are formed
by linking the heavy and light chain fragments of the Fv region via
an amino acid bridge, resulting in a single chain polypeptide.
[0149] Antibody fragments, which recognise specific epitopes, may
be generated by known techniques. For example, such fragments
include, but are not limited to, the F(ab').sub.2 fragments which
can be produced by pepsin digestion of the antibody molecule and
the Fab fragments which can be generated by reducing the disulfide
bridges of the F(ab').sub.2 fragments. Alternative, Fab expression
libraries may be constructed (Huse, et al., 1989, Science 246:
1275-1281) to allow rapid and easy identification of monoclonal Fab
fragments with the desired specificity.
3 Assays for Amelioration of Alzheimer's Disease Symptoms
[0150] The differentially expressed proteins described herein may
used to test compounds for the ability to prevent or ameliorate
Alzheimer's disease.
[0151] Such compounds may be tested in human subjects in clinical
trials. Any compound which restores the expression of a
differentially expressed protein or proteins towards the normal
level may be of potential use in treating Alzheimer's disease, i.e.
reducing Alzheimer's disease symptoms or slowing the progression of
Alzheimer's disease.
[0152] With regard to intervention, any treatments that restore or
partially restore marker protein expression to normal levels should
be considered as candidates for Alzheimer's disease therapeutic
intervention. Dosages of test agents may be determined by deriving
dose-response curves, as discussed in Section 6 below.
[0153] Similarly, any treatments that can prevent the development
of Alzheimer's disease or prevent progression to levels of more
advanced Alzheimer's disease should be considered as candidates for
the Alzheimer's disease therapeutic intervention.
[0154] In addition, animal models of Alzheimer's disease, such as
those described above, may be used to identify compounds capable of
treating Alzheimer's disease symptoms. Such animal models may be
used as test substrates for the identification of drugs,
pharmaceuticals, therapies and interventions which may be effective
in treating such disorders. The response of the animals to the
exposure may be monitored by assessing the expression of the marker
proteins and comparing it to that of wild-type mice.
[0155] Protein expression patterns may be utilised in conjunction
with animal model systems to assess the ability of a compound to
ameliorate Alzheimer's disease symptoms, or prevent the progression
of Alzheimer's disease. For example, the expression pattern of one
or more fingerprint proteins may form part of a fingerprint
profile, which may then be used in such an assessment. Fingerprint
profiles may be characterised for Alzheimer's disease states within
the animal model systems. Subsequently, these known fingerprint
profiles may be compared to ascertain the effect a test compound
has to modify such fingerprint profiles, and to cause the profile
to more closely resemble that of a more desirable fingerprint. For
example, administration of a compound may cause the fingerprint
profile of an Alzheimer's disease model system to more closely
resemble the control system, or may prevent further changes in
fingerprint profile. Administration of a compound may,
alternatively, cause the fingerprint profile of a control system to
begin to mimic an Alzheimer's disease state, which may, for
example, be used in further characterising the compound of
interest, or may be used in the generation of additional animal
models.
4. Compounds and Methods for Treatment of Alzheimer's Disease
[0156] Described below are methods and compositions whereby
Alzheimer's disease symptoms may be ameliorated or the progression
of Alzheimer's disease slowed or halted. It is possible that
Alzheimer's disease symptoms may be brought about, at least in
part, by an abnormal level of target protein, or by the presence of
a target protein exhibiting an abnormal activity. As such, the
reduction in the level and/or activity of such target protein would
bring about the amelioration Alzheimer's disease symptoms.
Techniques for the reduction of target protein gene expression
levels or target protein activity levels are discussed in Section
4.1.
[0157] Alternatively, it is possible that Alzheimer's disease
symptoms may be brought about, at least in part, by the absence or
reduction of the level of target protein expression, or a reduction
in the level of a target protein's activity. As such, an increase
in the level of target protein gene expression and/or the activity
of such proteins would bring about the amelioration Alzheimer's
disease symptoms. Techniques for increasing target protein gene
expression levels or target protein activity levels are discussed
in Section 4.2.
4.1 Compounds that Inhibit Expression, Synthesis or Activity of
Target Proteins
[0158] As discussed above, target proteins involved in Alzheimer's
disease may cause such disorders via an increased level of target
protein activity. A variety of techniques may be utilised to
inhibit the expression, synthesis, or activity of such target genes
and/or proteins.
[0159] For example, compounds which exhibit inhibitory activity,
may be used in accordance with the invention to prevent mild
cognitive impairment or Alzheimer's disease symptoms. Such
molecules may include, but are not limited to, peptides (such as,
for example, peptides representing soluble extracellular portions
of target protein transmembrane receptors), phosphopeptides, small
organic or inorganic molecules, or antibodies (including, for
example, polyclonal, monoclonal, humanised, anti-idiotypic,
chimeric or single chain antibodies, and FAb, F(ab').sub.2 and FAb
expression library fragments, and epitope-binding fragments
thereof). Techniques for determination of effective doses and
administration of such compounds are described below, in Section
6.1. Inhibitory antibody techniques are further described below, in
Section 4.1.2.
[0160] Further, antisense, siRNA and ribozyme molecules, which
inhibit expression of the target protein gene, may also be used in
accordance with the invention to inhibit the aberrant target
protein gene activity. Such techniques are described below, in
Section 4.1.1; triple helix molecules may be utilised in inhibiting
the aberrant target protein gene activity.
4.1.1 Inhibitory Antisense, Ribozyme and Triple Helix
Approaches
[0161] Antisense, ribozyme and triple helix molecules may be
designed to reduce or inhibit either wild type, or if appropriate,
mutant target protein gene activity. Techniques for the production
and use of such molecules are well known to those of skill in the
art.
[0162] Antisense RNA and DNA molecules act to directly block the
translation of mRNA by hybridising to targeted mRNA and preventing
protein translation. With respect to antisense DNA,
oligodeoxy-ribonucleotides derived from the translation initiation
site, e.g. between the -10 and +10 regions of the target gene
nucleotide sequence of interest, are preferred.
[0163] Ribozymes are enzymatic RNA molecules capable of catalysing
the specific cleavage of RNA. (For a review, see Rossi, J., 1994,
Current Biology 4: 469-471). The mechanism of ribozyme action
involves sequence specific hybridisation of the ribozyme molecule
to complementary target RNA, followed by a endonucleolytic
cleavage. The composition of ribozyme molecules must include one or
more sequences complementary to the target protein mRNA, and must
include the well known catalytic sequence responsible for mRNA
cleavage. For this sequence, see U.S. Pat. No. 5,093,246. As such,
within the scope of the invention are engineered hammerhead motif
ribozyme molecules that specifically and efficiently catalyse
endonucleolytic cleavage of RNA sequences encoding target
proteins.
[0164] Specific ribozyme cleavage sites within any potential RNA
target are initially identified by scanning the molecule of
interest for ribozyme cleavage sites which include the following
sequences, GUA, GUU and GUC. Once identified, short TNA sequences
of between 15 and 20 ribonucleotides corresponding to the region of
the target protein gene, containing the cleavage site may be
evaluated for predicted structural features, such as secondary
structure, that may render the oligonucleotide sequence unsuitable.
The suitability of candidate sequences may also be evaluated by
testing their accessibility to hybridise with complementary
oligonucleotides, using ribonuclease protection assays.
[0165] RNA interference (RNAi) is a process of sequence-specific,
post-transcriptional gene silencing in animals and plants,
initiated by double-stranded RNA (dsRNA) that is homologous in
sequence to the silenced gene. RNAi is mediated by short
double-stranded RNA molecules (small interfering RNAs or siRNAs).
siRNAs may be introduced into a cell as short RNA oligonucleotides
of 10-15 bp, or as longer dsRNAs which are subsequently cleaved to
produce siRNAs. The RNA may be introduced into the cell as RNA, or
may be transcribed from a DNA or RNA vector.
[0166] siRNA molecules may be synthesized using standard solid or
solution phase synthesis techniques which are known in the art.
Alternatively, siRNA molecules or longer dsRNA molecules may be
made recombinantly by transcription of a nucleic acid sequence,
preferably contained within a vector as described below.
[0167] Another alternative is the expression of a short hairpin RNA
molecule (shRNA) in the cell. shRNAs are more stable than synthetic
siRNAs. A shRNA consists of short inverted repeats separated by a
small loop sequence. One inverted repeat is complimentary to the
gene target. The shRNA is then processed into an siRNA which
degrades the target gene mRNA and suppresses expression. shRNAs can
produced within a cell by transfecting the cell with a DNA
construct encoding the shRNA sequence under control of a RNA
polymerase III promoter, such as the human Hi or 7SK promoter.
Alternatively, the shRNA may be synthesised exogenously and
introduced directly into the cell. Preferably, the shRNA sequence
is between 40 and 100 bases in length, more preferably between 40
and 70 bases in length. The stem of the hairpin is preferably
between 19 and 30 base pairs in length. The stem may contain G-U
pairings to stabilise the hairpin structure.
[0168] Nucleic acid molecules to be used in triplex helix formation
for the inhibition of transcription should be single stranded and
composed of deoxynucleotides. The base composition of these
oligonucleotides must be designed to promote triple helix formation
via Hoogsteen base pairing rules, which generally require sizeable
stretches of either purines or pyrimidines to be present on one
strand of a duplex. Nucleotide sequences may be pyrimidine-based,
which will result in TAT and CGC.sup.+ triplets across the three
associated strands of the resulting triple helix. The
pyrimidine-rich molecules provide base complementary to a
purine-rich region of a single strand of the duplex in a parallel
orientation to that strand. In addition, nucleic acid molecules may
be chosen that are purine-rich, for example, containing a stretch
of G residues. These molecules will form a triple helix with a DNA
duplex that is rich in GC pairs, in which the majority of the
purine residues are located on a single strand of the targeted
duplex, resulting in GGC triplets across the three strands in the
triplex.
[0169] Alternatively, the potential sequences that can be targeted
for triple helix formation may be increased by creating a so-called
"switchback" nucleic acid molecule. Switchback molecules are
synthesised in an alternating 5'-3',3'-5' manner, such that they
base pair with first one strand of a duplex and then the other,
eliminating the necessity for a sizeable stretch of either purines
or pyrimidines to be present on one strand of a duplex.
[0170] Anti-sense RNA and DNA, siRNAs, ribozyme and triple helix
molecules of the invention may be prepared by any method known in
the art for the synthesis of DNA and RNA molecules. They include
techniques for chemically synthesising oligodeoxyribonucleotides
and oligo-ribonucleotides well known in the art such as, for
example, solid phase phosphoramidite chemical synthesis.
Alternatively, RNA molecules may be generated by in vitro and in
vivo transcription of DNA sequences encoding the antisense RNA
molecule. Such DNA sequences may be incorporated into a wide
variety of vectors, which incorporate suitable RNA polymerase
promoters such as the T7 or SP6 polymerase promoters.
Alternatively, antisense cDNA constructs that synthesise antisense
RNA constitutively inducibly, depending on the promoter used, can
be introduced stably into cell lines.
4.1.2 Antibodies for the Inhibition of Target Protein
[0171] Antibodies that are both specific for target protein and
interfere with its activity may be used to inhibit target protein
function. Where desirable, antibodies specific for mutant target
protein, which interferes with the activity of such mutant target
product, may also be used. Such antibodies may be generated, using
standard techniques described in Section 2. above, against the
proteins themselves or against peptides corresponding to portions
of the proteins. The antibodies include, but are not limited to,
polyclonal, monoclonal, Fab fragments, single chain antibodies,
chimeric antibodies, etc.
[0172] In instances where the target gene protein is intracellular
and whole antibodies are used, internalising antibodies may be
preferred. However, lipofectin or liposomes may be used to deliver
the antibody or a fragment of the Fab region, which binds to the
target protein epitope into cells. Where fragments of the antibody
are used, the smallest inhibitory fragment, which binds to the
target protein's binding domain, is preferred. For example,
peptides having an amino acid sequence corresponding to the domain
of the variable region of the antibody that binds to the target
protein may be used. Such peptides may be synthesised chemically or
produced via recombinant DNA technology using methods well known in
the art (e.g. see Creighton, 1983, supra; and Sambrook et al, 1989,
supra).
[0173] Alternatively, single chain neutralising antibodies, which
bind to intracellular target protein epitopes, may also be
administered. Such single chain antibodies may be administered, for
example, by expressing nucleotide sequences encoding single-chain
antibodies within the target cell populating by utilising, for
example, techniques such as those described in Marasco et al
(Marasco, W. et al, 1993, Proc. Natl. Acad. Sci. USA, 90:
7889-7893).
[0174] In instances where the target protein is extracellular, or
is a transmembrane protein, any of the administration techniques
described below, in Section 6, which are appropriate for peptide
administration may be utilised to effectively administer inhibitory
target protein antibodies to their site of action.
4.2 Methods for Restoring Target Protein Activity
[0175] Target proteins that cause Alzheimer's disease may be
underexpressed in Alzheimer's disease disorder situations.
Alternatively, the activity of target protein may be diminished,
leading to the development of Alzheimer's disease symptoms.
Described in this Section are methods whereby the level of target
protein may be increased to levels wherein Alzheimer's disease
symptoms are prevented or ameliorated. The level of target protein
activity may be increased, for example, by either increasing the
level of target protein present or by increasing the level of
active target protein which is present.
[0176] For example, a target protein, at a level sufficient to
ameliorate Alzheimer's disease symptoms may be administered to a
patient exhibiting such symptoms. Any of the techniques discussed
below, in Section 6, may be utilised for such administration. One
of skill in the art will readily know how to determine the
concentration of effective, non-toxic doses of the normal target
protein, utilising techniques such as those described below.
[0177] Further, patients may be treated by gene replacement
therapy. One or more copies of a normal target protein gene or a
portion of the gene that directs the production of a normal target
protein with target protein gene function, may be inserted into
cells, using vectors which include, but are not limited to,
adenovirus, adeno-associated virus, and retrovirus vectors, in
addition to other particles that introduce DNA into cells, such as
liposomes. Additionally, techniques such as those described above
may be utilised for the introduction of normal target protein gene
sequences into human cells.
[0178] Cells, preferably autologous cells, containing normal target
protein gene sequences may then be introduced or reintroduced into
the patient at positions which allow for the prevention or
amelioration of Alzheimer's disease symptoms. Such cell replacement
techniques may be preferred, for example, when the target protein
is a secreted, extracellular protein.
[0179] Additionally, antibodies may be administered which
specifically bind to a target protein and by binding, serve to,
either directly or indirectly, activate the target protein
function. Such antibodies can include, but are not limited to,
polyclonal, monoclonal, FAb fragments, single chain antibodies,
chimeric antibodies and the like. The antibodies may be generated
using standard techniques such as those described above, in Section
2.3, and may be generated against the protein themselves or against
proteins corresponding to portions of the proteins. The antibodies
may be administered, for example, according to the techniques
described above.
5. Pharmaceutical Preparations and Methods of Administration
[0180] The identified compounds, nucleic acid molecules and cells
that affect target protein expression, synthesis and/or activity
can be administered to a patient at therapeutically effective doses
to prevent or to treat or to ameliorate Alzheimer's disease. A
therapeutically effective dose refers to that amount of the
compound sufficient to result in amelioration of symptoms
Alzheimer's disease, or alternatively, to that amount of a nucleic
acid molecule sufficient to express a concentration of protein
which results in the amelioration of such symptoms.
5.1 Effective Dose
[0181] Toxicity and therapeutic efficacy of such compounds can be
determined by standard pharmaceutical procedures in cell cultures
or experimental animals, e.g. for determining by ED.sub.50 (the
dose therapeutically effective in 50% of the population) and by
determining the ED.sub.50 of any side-effects (toxicity--TD50). The
dose ratio between toxic and therapeutic effects is the therapeutic
index and it can be expressed as the ratio TD.sub.50/ED.sub.50.
Compounds, which exhibit large therapeutic indices, are preferred.
While compounds that exhibit toxic side effects may be used, care
should be taken to design a delivery system that targets such
compounds to the site of affected tissue in order to minimise
potential damage to uninfected cells and, thereby, reduce side
effects.
[0182] The data obtained from the animal studies can be used in
formulating a range of dosage for use in humans. The dosage of such
compounds lies preferably within a range of circulating
concentrations that include the ED.sub.50 with little or no
toxicity. The dosage may vary within this range depending upon the
dosage form employed and the route of administration utilised.
5.2 Formulations and Use
[0183] Pharmaceutical compositions for use in accordance with the
present invention may be formulated in conventional manner using
one or more physiologically acceptable carriers or excipients.
[0184] Thus, the compounds and their physiologically acceptable
salts and solvates may be formulated for administration by
inhalation or insufflation (either through the mouth or the nose)
or oral, buccal, parenteral and rectal administration.
[0185] For oral administration, the pharmaceutical compositions may
take the form of, for example, tablets or capsules prepared by
conventional means with pharmaceutically acceptable excipients such
as binding agents (e.g. pre-gelatinised maize starch,
polyvinylpyrrolidone or hydroxypropyl methyl-cellulose); fillers
(e.g. lactose, microcrystalline cellulose or calcium hydrogen
phosphate); lubricants (e.g. magnesium, stearate, talc or silica);
disintegrants (e.g. potato starch or sodium starch glycollate); or
wetting agents (e.g. sodium lauryl sulphate). The tablets may be
coated by methods well known in the art. Liquid preparations for
oral administration may take the form of, for example, solutions,
syrups or suspensions, or they may be presented as a dry product
for constitution with water or other suitable vehicle before use.
Such liquid preparations may be prepared by conventional means with
pharmaceutically acceptable additives such as suspending agents
(e.g. sorbitol syrup, cellulose derivatives or hydrogenated edible
fats); emulsifying agents (e.g. lecithin or acacia); and
preservatives (e.g. methyl or propyl-p-hydroxybenzoates or sorbic
acid). The preparations may also contain buffer salts, flavouring,
colouring and sweetening agents as appropriate.
[0186] Preparations for oral administration may be suitably
formulated to give controlled release of the active compound.
[0187] For buccal administration the compositions may take the form
of tablets or lozenges formulated in conventional manner.
[0188] For administration by inhalation, the compounds for use
according to the present invention are conveniently delivered in
the form of an aerosol spray presentation from pressurised packs or
a nebuliser, with the use of a suitable propellant, e.g.
dichlorodifluoromethane, trichlorofluoromethane,
dichloro-tetrafluoroethane, carbon dioxide or other suitable gas.
In the case of a pressurised aerosol the dosage unit may be
determined by providing a valve to deliver a metered amount.
Capsules and cartridges of, e.g. gelatin, for use in an inhaler or
insufflator may be formulated containing a powder mix of the
compound and a suitable powder base such as lactose or starch.
[0189] The compounds may be formulated for parenteral
administration by injection, e.g. by bolus injection or continuous
infusion. Formulations for injection may be presented in unit
dosage form, e.g. in ampoules or in multi-dose containers, with an
added preservative. The compositions may take such forms as
suspensions, solutions or emulsions in oily or aqueous vehicles,
and may contain formulatory agents such as suspending, stablising
and/or dispersing agents. Alternatively, the active ingredient may
be in powder form for constitution with a suitable vehicle, e.g.
sterile pyrogen-free water, before use.
[0190] The compounds may also be formulated in rectal compositions
such as suppositories or retention enemas, e.g. containing
conventional suppository bases such as cocoa butter or other
glycerides.
[0191] In addition to the formulations described previously, the
compounds may also be formulated as a depot preparation. Such long
acting formulations may be administered by implantation, for
example, subcutaneously or intramuscularly) or by intramuscular
injection. Thus, for example, the compounds may be formulated with
suitable polymeric or hydrophobic materials (for example, as an
emulsion in an acceptable oil) or ion exchange resins, or as
sparingly soluble derivatives, for example, as a sparingly soluble
salt.
[0192] The compositions may, if desired, be presented in a pack or
dispenser device, which may contain one or more unit dosage forms
containing the active ingredient. The pack may, for example,
comprise metal or plastic foil, such as blister pack. The pack or
dispenser device may be accompanied by instructions for
administration.
6. Diagnosis of Alzheimer's Disease
[0193] A variety of methods may be employed for the diagnosis of
Alzheimer's disease, monitoring progression of mild cognitive
impairment and Alzheimer's disease, the predisposition to
Alzheimer's disease, and for monitoring the efficacy of any
Alzheimer's disease compounds during, for example, clinical trials
and for monitoring patients undergoing clinical evaluation for the
treatment of Alzheimer's disease. The differentially expressed and
fingerprint proteins can also be used to define the nature or
degree of Alzheimer's disease to aid in the identification and/or
selection of treatments for the disorder.
[0194] Alzheimer's disease is characterised by a progressive,
insidious onset, two or more deficits in cognitive function, and
the absence of any other illnesses that could account for the
dementia
[0195] In addition to memory loss, there may be disorientation,
poor attention span, and language impairment. There is likely to be
a decline in the activity of daily living, and possibly also
impaired perception and personality changes. Behavioural symptoms
include delusions, aggression, agitation, anger, wandering,
hallucinations, and sleep disturbance.
[0196] A simple test assessing orientation, registration,
calculations and attention, recall, language, and visual-spatial
function may be used for an initial diagnosis.
[0197] Structural imaging by standard CT or MRI may also be used.
Typically a non-contrast head CT scan suffices, but MRI is
preferred for those who have hypertension or diabetes, who are at
risk for cerebral vascular disease.
[0198] Alzheimer's disease may be confirmed histologically by
autopsy or brain biopsy showing neurofibrillary tangles and senile
plaques.
[0199] Identifying individuals at risk from Alzheimer's disease may
involve diagnosis of mild cognitive impairment (MCI). (MCI) may be
a transitional state between normal aging and dementia. There are
different types of MCI. There may be cognitive impairment in
multiple areas of cognitive function, in addition to memory. In
some cases, memory is normal but some other domain of cognitive
function is abnormal.
[0200] Amnestic MCI appears to be a risk state for the development
of Alzheimer's disease. Amnestic impairment is defined by
subjective memory complaints. These patients have poor memory
performance for their age and education on formal testing when
compared to age-matched peers. General cognitive functions and the
ability to perform the activities of daily living should be
entirely normal. The amnestic type of MCI is associated with
hippocampal atrophy, neurofibrillary tangles in the medial temporal
lobes, and elevated levels of Tau in the cerebrospinal fluid
(CSF).
[0201] Methods for diagnosing Alzheimer's disease or predisposition
to Alzheimer's disease may also, for example, utilise reagents such
as the differentially expressed and fingerprint proteins described
above, and antibodies directed against differentially expressed, as
described above. Specifically, such reagents may be used for the
detection of either an over- or an under-abundance of target
protein relative to the normal state.
[0202] The methods described herein may be performed, for example,
by utilising pre-packaged diagnostic kits comprising at least one
specific differentially expressed/finger print protein or
anti-differentially expressed/fingerprint protein antibody reagent
described herein, which may be conveniently used, e.g. in clinical
settings, to diagnose patients exhibiting Alzheimer's disease
symptoms.
[0203] Any cell type, tissue or body fluid in which the fingerprint
protein is expressed may be utilised in the diagnostics described
herein. Examples of suitable samples types include cell samples,
tissue samples, and fluid samples such as blood, urine, serum,
saliva, cerebrospinal fluid or plasma.
[0204] Among the methods which can be utilised herein, are methods
for monitoring the efficacy of compounds in clinical trials for the
treatment of Alzheimer's disease. Such compounds can, for example,
be compounds such as those described above, in Section 4. Such a
method comprises detecting, in a patient sample, a protein, which
is differentially expressed in the Alzheimer's disease state
relative to its expression in a normal state.
[0205] During clinical trials, for example, the expression of a
single differentially expressed protein, or alternatively, a
fingerprint pattern of a cell involved in Alzheimer's disease can
be determined in the presence or absence of the compound being
tested. The efficacy of the compound can be followed by comparing
the expression data obtained to the corresponding known expression
patterns in a normal state. Compounds exhibiting efficacy are those
which alter the protein expression and/or the fingerprint pattern
to more closely resemble that of the normal state, or which
stabilise protein expression and/or the fingerprint pattern i.e.
prevent progression of the disease.
[0206] The detection of the protein differentially expressed in the
Alzheimer's disease state relative to their expression in a normal
state can also be used for monitoring the efficacy of potential
compounds for the treatment of Alzheimer's disease during clinical
trials. During clinical trials, for example, the level and/or
activity of the differentially expressed protein can be determined
in relevant cells and/or tissues and/or body fluids in the presence
or absence of the compound being tested. The efficacy of the
compound can be followed by comparing the protein level and/or
activity data obtained to the corresponding known levels/activities
for the cells and/or tissues and/or body fluids in a normal state.
Compounds exhibiting efficacy are those which alter the pattern of
the cell and/or tissue sample and/or body fluid from an Alzheimer's
disease subject to more closely resemble that of the normal state
or which stabilise the pattern i.e. prevent progression of the
disease.
EXPERIMENTAL
Subjects
[0207] The study population is derived from a large, longitudinally
assessed, community based population of people with AD
(NINCDS-ADRDA probable), other dementias and normal elderly
persons. Samples are available on over 1000 subjects, all whom have
detailed clinical assessment. Clinical research data includes
systematic diagnostic, cognitive and behavioural assessments.
Approximately 50 ml blood (4.times.10 ml in BD vacutainer K3E 15%
tubes and 1.times.10 ml in exetainer) is drawn from each subject.
Subjects have had no food or fluid intake for more than 2 hours
prior to collection. One BD vacutainer K3E (plasma) and exetainer
(serum) is used for proteomics study. The serum/plasma samples
collected for proteomics are spun at 3000 rpm for 8 min within 2 h
of collection.
Analysis
[0208] Serum/plasma samples were lysed and rehydrated in a 2D lysis
buffer consisting of 8M Urea, 2% w/v CHAPS, 0.5% IPG Pharmalyte (pH
3-10; Amersham Biotech, UK. The lysed samples were then subjected
to isoelectrofocusing 18 cm 3-10 NL Immobiline pH gradient strips.
IPG electrofocusing of the rehydrated strips was carried out for 16
h using the following protocol: S1 500V step-n-hold (s/h; i.e. the
electric current applied to the strip is gradually increased in
steps holding at particular settings for the times indicated) for 1
h; S2 500V s/h for 2 h; S3 1000V gradient (G) for 1 h; S4 1000V s/h
for 2 h; S5 8000V G for 2 h and a final step S6 8000V s/h for 8 h
with the IPGphor.TM..
[0209] Electrofocused IPG strips were then equilibrated in a SDS
equilibration buffer (50 mM Tris-HCl pH8.8, 6M urea, 30% (v/v)
glycerol, 2% SDS, and trace amount of bromophenol blue) with 10
mg/ml dithiothreitol (DTT) for 20 min, followed by 20 min step with
25 mg/ml Iodoacetamide. The equilibrated strips were then separated
on a 10% acrylamide second dimension electrophoresis gel using the
Ettan Dalt II system.
[0210] Following the electrophoresis the gels were placed in
separate staining boxes and fixed using 40% ethanol/10% acetic acid
for 1 h at room temperature and then stained according to
Hochstrasse protocol (Table 1). Gel analysis was performed using
the Melanie 3 software and Mann and Whitney rank sum test and False
Discovery Rate statistical analysis was carried out to compare
subject groups.
TABLE-US-00001 TABLE 1 Hochstrasse staining protocol Staining step
Time Fix 40% ethanol/10% acetic 1 h acid Soak in 5% ethanol/5%
acetic 3 hr or acid overnight Wash in water 5 min Soak in 0.5M
Sodium acetate, 1.5 h 1% gluteraldehyde Wash 4 .times. 15 min Soak
in 0.05% Naphthalene 2 .times. 30 min sulphonic acid Rinse in water
4 .times. 15 min Silver stain (12 g silver, 20 ml 25 min ammonium
hydroxide and 3 ml 10M sodium hydroxide) Wash 4 .times. 4 min
Develop (0.005% citric acid As and 0.1% formaldehyde) required Stop
solution (5% tris and 2% 1-2 h acetic acid) Storage solution (35%
ethanol and 5% glycerol)
Sample Preparation
[0211] In-gel reduction, alkylation and digestion (with trypsin)
were performed prior to subsequent analysis by mass spectrometry.
Cysteine residues were reduced with DTT and derivatized by
treatment with iodoacetamide to form stable carbamidomethyl (CAM)
derivatives. Trypsin digestion was carried out overnight at room
temperature after an initial 1 hr incubation at 37.degree. C.
MALDI-TOF Mass Spectrometry
[0212] The digested sample (3 .mu.l) was desalted and concentrated
using ZipTipC18 microtips (Millipore). Peptides were eluted in 4
.mu.l 50% acetonitrile/0.1% trifluoroacetic acid. 0.5 .mu.l was
then loaded onto a target plate with 0.5 .mu.l matrix
(.alpha.-Cyano-4-hydroxy-cinnamic acid). Peptide mass fingerprints
were acquired using a Voyager De-Pro, MALDI-TOF mass spectrometer
(Applied Biosystems). The mass spectra were acquired in reflectron
mode with delayed extraction. An autolytic tryptic peptide of mass
2163.0569 Da was then used to lock mass the acquired spectra, to
achieve a mass accuracy of better than 30 ppm.
LC/MS/MS
[0213] Peptides were extracted from the gel pieces by a series of
acetonitrile and aqueous washes. The extract was pooled with the
initial supernatant and lyophilised. Each sample was then
resuspended in 6 .mu.L of 50 mM ammonium bicarbonate and analysed
by LC/MS/MS. Chromatographic separations were performed using an
Ultimate LC system (Dionex, UK). Peptides were resolved by reverse
phase chromatography on a 75 .mu.m C18 PepMap column. A gradient of
acetonitrile in 0.05% formic acid was delivered to elute the
peptides at a flow rate of 200 nl/min. Peptides were ionised by
eLectrospray ionisation using a Z-spray source fitted to a
QTOFmicro (Waters Corporation). The instrument was set to run in
automated switching mode, selecting precursor ions based on their
intensity, for sequencing by collision-induced fragmentation. The
MS/MS analyses were conducted using collision energy profiles that
were chosen based on the m/z and the charge state of the
peptide.
Results
[0214] Analysis of all control group (n=50) and case group
[0215] (n=50) 2D gel images and subjecting them to statistical
analysis. A total of 16 protein spots show a significant result
(p<0.05) (see FIG. 6).
[0216] The results shown in FIG. 6 are unambiguous matches as they
are based on exact matching of multiple MS/MS spectra. The sequence
of selected proteins showing the peptide coverage obtained is given
in FIGS. 8 to 10.
Class Prediction Using Peptide Fingerprinting
[0217] A class prediction analysis was performed in order to
determine whether the pattern of peptide spots on 2DGE could
predict caseness as determined clinically. Support Vector Machines
(SVM), a supervised machine learning algorithm for prediction of
class set in a group based upon a training set of data.sup.13, was
used. SVM is most typically used in microarray analyses. However
the statistical challenges are similar for proteomics and SVM has
previously been used as a class prediction model for various
proteomic studies.sup.14,15. Using GeneSpring (Silicon Genetics)
the original 25 cases and 25 controls were designated as a training
set and then the replication 25 cases and 25 controls designated as
a test set. All identified proteins were used as possible
identifiers and with the parameters Polynomial Dot Product Order 1
and Diagonal Scaling Factor 1; 34 of the 50 test-samples were
correctly identified as being either cases or controls. Sensitivity
was 56% and specificity 80% using SVM analysis of 2DGE data
alone.
Identification of Peptides that Differentiate Between Cases and
Controls
[0218] The normalised spot optical density in both the initial set
of cases and controls and the replication set was compared. Mean
differences between patients and controls at each spot were
compared using the Wilcoxen rank-sum (Mann-Whitney) tests. The
p-values for the nul hypothesis of no mean differences were saved,
sorted by increasing value and ranked. A false discovery rate index
(FDR) was computed as the ratio of the rank number and the
theoretical probability (which is the rank number divided by the
total number of spots). Fifteen spots were identified to have a FDR
of less than 0.50 These were then identified using LC-MS/MS (FIG.
6).
Correlation of Peptide Spots with Clinical Parameters
[0219] Although the cases and controls were similarly aged it was
possible that the observed peptide or spot differences were due to
an association with age, gender or APOE genotype. A correlation
analysis was thus performed for the 15 spots that differed between
cases and controls in all 100 subjects with age, gender and APOE
genotype. Data was first scaled to unit variance so as to
standardise the scales upon which the variables were compared (i.e.
each value was divided by the standard deviation of all the values
for that particular variable). The Pearson correlation coefficient
was then calculated. Cases with missing values were excluded
pairwise. There were no strong correlations of any spot with age,
gender or APOE. Two spots weakly correlated with age, two with
gender and one with APOE genotype.
[0220] An ideal biomarker would not only be different between cases
and controls but would be a marker of disease progression. The 15
spots showing case-control differences in all 50 cases were thus
correlated with duration of dementia and severity as measured by
MMSE and GDS. Two spots correlated moderately and significantly
with measures of disease progression and global dementia severity
(r.sup.2=0.29 with spot 177) and duration of disease (r.sup.2=-0.29
with spot 166). Thus, one peptide--an Ig lambda chain C region
(spot 177) correlates with global dementia severity. The other
marker of disease progression examined, duration, shows a negative
correlation with albumin (Spot 165).
Pre-Depletion Analysis
[0221] In these experiments, human plasma samples were depleted to
remove the 6 most abundant proteins before the 2D gel
electrophoresis step.
Methods
[0222] 60 human plasma samples (30 Controls and 30 disease
subjects) were depleted using a removal column from Agilent. The
samples were separated by 2D electrophoresis (pH 3-10 NL, 10%
SDS-PAGE, 75 .mu.g protein load). Gels were silver-stained, scanned
(8 bit, 200 dpi) and quantitatively analysed with Progenesis. To
pick gel plugs from preparative gels, several control samples were
mixed together and 3 gels run (2 gels with 205 .mu.g protein load
and 1 gel with 350 .mu.g protein load). The same strategy was used
with disease samples to run preparative gels. Protein spots were
then de-stained, trypsinated and polypeptides were spotted onto
MALDI target with Spot handling workstations (GE Amersham
Biosciences). Peptide profiles generated were analysed with Ms-Fit
programme in combination with the Swiss-Prot database.
Results
[0223] Gel images of proteins extracted from control and disease
samples were analysed with Progenesis (v2005). Each group (Control
and Disease) were based on 29 analytical gels. Spot detection,
matching were performed with Progenesis, then the spot data were
exported to Excel and a macro developed in-house was used to
calculate coefficient of variation (CV %), T-Test and Regulation
facto or change.
[0224] 11 spots were selected for analysis based on the following
selection criteria: spots have to be found within at least 60% of
gels, 2-fold up/down regulation and p value<0.005. FIG. 11
displays the location of these 11 spots in the reference gel. This
image corresponds to the 2D profile of proteins extracted from a
control sample. The normalised volumes of the 11 spots detected in
gels was analysed and is given in FIG. 12.
[0225] All protein spots were picked from 3 to 6 different
preparative gels and submitted to MS analyses. All protein spots
were successfully identified as shown in FIG. 12. In the down
regulated spots, we found two spots of alpha-2-macroglobulin
precursor (174; 178), one spot of inter-alpha-trypsin inhibitor
heavy chain H4 precursor (232), one spot of a mix of complement C3
precursor with clusterin precursor (712) as indicated in grey in
FIG. 12 and one spot of complement C3 precursor (713). In the up
regulated spots, we found two spots of complement C4 precursor
(652; 832), one spot of actin (675) and three spots of haptoglobin
precursor (702; 703; 706).
[0226] To estimate the coverage of proteins identified and to
discriminate the different chains or isoforms, for each spot, a
common list of peptide masses was established.
[0227] This list regroups all peptide masses matched corresponding
to the same spot picked in 3 to 6 preparative gels. The amino acids
belonging to the peptides matched are underlined in FIGS. 13 to
19.
Discussion
[0228] The 11 spots analysed identified 7 regulated proteins
between control- and disease samples, namely alpha-2-macroglobulin,
inter-alpha-trypsin inhibitor heavy chain H4, complement C3,
complement C4, actin cytoplasmic and haptoglobin.
[0229] Alpha-2-macroglobulin protein is able to inhibit all four
classes of proteinases by a unique "trapping" mechanism. The
observed molecular weight of the gel spots (.about.100 kDa, FIG.
11, spots 174; 178), matched by PMF, cover mainly the N-terminus of
the protein (FIG. 14). The protein identified may thus correspond
to a fragment of the full-length sequence of alpha-2-macroglobulin.
As spots identified as alpha-2-macroglobulin belong to the same
chain of spots (FIG. 11), it is possible that the difference
between the two spots may be due to a post-translation
modification.
[0230] There are two isoforms of inter-alpha-trypsin inhibitor
heavy chain H4. Isoform 1 has 930 amino-acids and isoform 2 has 914
amino-acids. This protein is cleaved by plasma kallikrein to yield
100 kDa and a 35 kDa fragments. The resulting 100 kDa fragment is
further converted to a 70 kDa fragment. The masses matched by PMF
cover the sequence up to amino acid (aa) 688. This sequence
corresponds to isoform 1 and may include the 70 kDa fragment and a
short potentially active peptide. In this case, there is good
agreement between the theoretical molecular weight and pI (74 kDa
and 6.04 respectively) and the observed ones from the gel spot (see
FIG. 11, spot 232).
[0231] Complement C3 precursor plays a central role in the
activation of the complement system. This protein contains two
chains (alpha and beta). We identified peptide masses covering the
sequence from aa 714 to aa 1360 (FIG. 15), which corresponds to the
alpha chain of complement C3. The theoretical molecular weight and
pI of the alpha chain (115 kDa and 5.55 respectively) are not in
agreement with the observed ones from the gel spots (see FIG. 11,
spots 712, 713). The alpha chain is processed into different
fragments. It appears that a temporary peptide appearing during the
activation of complement system. As spots identified as complement
C3 belong to the same chain of spots (FIG. 11), it is possible that
the difference is due to a post-translational modification.
[0232] Complement C4 plays a central role in the activation of the
classical pathway of the complement system. This protein contains
three chains (alpha, beta and gamma). We identified peptide masses
covering the alpha and beta chains for spot 832 and only alpha
chain for spot 652 (FIG. 17). The theoretical molecular weights and
pIs of these chains differ from the observed ones from the gel
spots (see FIG. 11, spots 652; 832). As for complement C3,
clusterin precursor protein contains two chains (alpha and beta).
We identified peptide masses covering the alpha and beta chains
(FIG. 16). The theoretical molecular weight and pI of clusterin (50
kDa and 5.89 respectively) are in agreement with those from the gel
(FIG. 11, spot 712). It appears the full-length protein was
identified.
Surface Enhanced Laser Desorption Ionisation Time of Flight Mass
Spectrometry [SELDI-TOF-MS].
[0233] SELDI-TOF-MS and ProteinChip technology were combined to
identify protein peaks differing between Alzheimer's and control
subjects, followed by extraction of material from the chips to
allow further characterisation of the material and identification
of the components present.
METHOD (SELDI Analysis)
[0234] The SELDI analysis comprises of a comparison of AD cases and
control samples and data has been obtained for both a set of
individual samples as well as a pooled set of samples. In each case
spectral profiles of sera from control and AD cases were
compared.
A). Analysis of a Set of Individuals
[0235] Control and AD sera from individuals were run on Q10-SAX2
chips:
n=4 control n=4 AD
[0236] Serum samples were prepared fresh by diluting 20 .mu.l serum
with 30 .mu.l SELDI lysis buffer. Five microlitres of sample were
spotted onto each spot as necessary.
[0237] The chips were processed using the following protocol:
Chip Preparation
[0238] A hydrophobic ring is drawn around each spot using a PAP pen
and the PAP allowed to dry thoroughly by placing chip on the SELDI
machine for up to 25 minutes.
Sample Preparation
[0239] Serum diluted in SELDI lysis buffer using a 40:60 ratio (40
.mu.L serum+60 .mu.L lysis buffer). Typically, this dilution will
render the sample at a 20 mg/mL to 30 mg/mL concentration.
Therefore, using a 5 .mu.L aliquot of the lysis buffer sample will
enable between 100 .mu.g to 150 .mu.g protein to be loaded on each
spot.
[0240] Samples are vortexed and incubated on ice until ready to
use, then briefly centrifuged samples immediately before use (30
secs, 14,000 rpm).
Chip Equilibration
[0241] The chip is placed in a 15 mL Falcon tube and 10-15 mL 100
mM Tris buffer pH 9 at room temperature added, then mixed on a
rotary mixer for 5 minutes. The procedure is repeated twice.
Sample Application
[0242] After the last equilibration step, the chip is removed and
dried carefully with soft tissue. 5 .mu.L of sample is pipetted
onto each spot, the chip is placed in a sealed humidity chamber and
placed on a shaker for 30 minutes.
Chip Washing
[0243] After incubation, the sample is carefully removed from each
spot and the chip replaced in the Falcon tube. 10-15 mL 100 mM Tris
buffer pH 9 is added, and the Falcon tube mixed on a rotary mixer
and for 5 minutes. This is repeat four more times, then the chip
washed twice in double distilled water.
Chip Drying
[0244] After the last wash step, the chip is removed and dried
carefully with soft tissue, then left to air-dry at room
temperature for 25 minutes.
SPA Application
[0245] 2.times.0.6 .mu.L saturated SPA matrix (freshly made) is
pipette onto each spot. The first application is allowed to dry
before applying the second 0.6 .mu.L aliquot. The SPA is then left
to dry for up to 10 minutes on the SELDI machine.
[0246] The chips are then read on the SELDI machine.
[0247] The following criteria were applied for data analysis:
[0248] Clustering criteria: 5 s/n; 100% spectra; 0.3% mass; 2 s/n;
add est. peaks.
[0249] Normalisation: Total ion count between 3,000 and 30,000 Da
only.
Results
[0250] Spot to spot reproducibility between loadings of the same
sample was very good. Good correlation was achieved.
[0251] Patient to patient variability in both control and dementia
groups was observed. This may be due to differences in protein
amount as well as idiosyncratic differences. Using very stringent
clustering, 3 peaks were found to be statistically significant
(p=0.05) and these were visually verified to check validity. The
three peaks of interest (see FIGS. 1-3) are as follows:
TABLE-US-00002 Mr 6,430 Da 1.62 fold increase in abundance in AD p
= 0.027 Mr 14,640 Da 2.29 fold increase in abundance in AD p =
0.036 Mr 27,147 Da 2.82 fold increase in abundance in AD p =
0.004574
B) Analysis of Pooled Sets
[0252] A set of pooled samples were analysed using exactly the same
methods and criteria as described above. Here, however, we analysed
3 pooled AD samples versus 3 pooled controls where each pool
contains serum from at least 25 individuals. In this manner we have
encompassed samples from over 75 individuals with AD and compared
them against a control cohort representing 75 number of
individuals. Pooled groups are described as: AD Pool 1, 2 and 3
comprising of 25, 25 and 25 unique individuals respectively.
Similarly, the pooled controls are described as: Control Pool 1, 2
and 3 comprising of 25, 25 and 25 unique individuals
respectively.
Results
[0253] Using very stringent clustering, 1 peak was found to be
statistically significant (p=0.05) and this was visually verified
to check validity.
[0254] The peak of interest (see FIG. 4) is as follows:
TABLE-US-00003 Mr 14,646 Da 1.72 fold increase in abundance in AD p
= 0.037
SELDI Peak Identification Strategy
[0255] The differentially expressed proteins identified by SELDI
analysis were further analysed by SDS-PAGE. Bands corresponding to
the MW of differentially expressed proteins were excised for
analysis by mass spectroscopy.
[0256] Material was extracted from chips Q10 854 & 855
("individual" samples) by boiling for 10 minutes in Laemmli buffer
and control and disease spots were pooled into separate Eppendorf
tubes. Extracted material was separated using SDS-PAGE (18%,
tris-glycine, Novex) and the gel was initially stained with
Colloidal Coomassie Blue (CCB) but no bands were visualised.
Subsequently the same gel was re-stained using modified
(MS-compatible) silver stain (FIG. 5).
[0257] Six bands, between 11 and 20 kDa, were visualised and these
were excised from the 1st control lane for analysis by LC/MS/MS as
described above.
[0258] Identified proteins are shown in FIG. 7.
Further Analysis of Identified Proteins
Apolipoprotein A-IV
[0259] Sequence coverage obtained for apolipoprotein A-IV (P06727)
is shown in FIG. 9 for the 14.6 kDa band isolated on the Q10 SAX2
SELDI chip
[0260] The molecular weight of the biomarker of interest observed
within the SELDI profiling experiments was determined to be
14640+/-6 Da. The 14.6 kDa species is thought to be a fragment of
ApoA-IV based on the facts that the intact protein should be
observed at higher mass (45 kDa) and that the peptides observed in
the LC/MS/MS analysis only represented the C-terminal region of the
protein. The observed molecular weight is in good agreement with
the average molecular weight of 14636 Da predicted for residues
270-396 of the sequence defined for apolipoprotein A-IV within the
Swiss Prot database entry P06727.
[0261] Both authentic full length apolipoprotein A-IV and a
C-terminal fragment of apolipoprotein A-IV comprising of residues
270-396 may thus represent serum biomarkers of Alzheimer's
disease.
Complement C4 Precursor
[0262] Sequence coverage obtained for Complement C4 precursor
(P01028) in 2DE spot 164 is shown in FIG. 10. Spot 164 was
identified on the basis of several peptides indicated in underlined
bold and this defines the protein in Spot 164 as a C-Terminal
fragment extending from residues 1466-1744.
Quantitative Protein Sequence Tag (qPST) Analysis
[0263] 10 disease samples and 10 control samples were individually
immunodepleted for the 6 most highly abundant proteins. 2 pools
consisting of either the disease or the control samples were
generated and applied to the qPST procedure (precleavage with CNBr,
labelling with dimethylglycine, trypsination and fractionation by
strong cation exchange). The obtained SCX fractions were analysed
by LC-MS and LC-MSMS using the QTOF-II instrument following the
standard approach (LC-MS and LC-MSMS by three different data
acquisition methods)
Results
Identification of Proteins
[0264] As stated above, three different MSMS acquisition strategies
were employed:
[0265] 1. Data Dependent Analysis to obtain as many as possible
peptide ID's (1 mass window).
[0266] 2. Data acquisition by an `include list` containing
regulated pairs, ie peptides whose intensity varied between disease
and control samples (regulation criteria:
.gtoreq.2/.gtoreq.0.5)
[0267] 3. Data acquisition by an `include list` containing
non-paired MS-signals.
[0268] Taking all results from these three approaches into account
and correcting them for redundancy, 88 protein IDs were
obtained.
Directed Searching for Regulated Proteins by Include List (Pairs
with a Regulation .gtoreq.2.0/.gtoreq.0.5) MSMS Strategy and
Crossmatching:
[0269] 8 peptides were identified which could be crossmatched to
regulations. These 8 peptides represent five proteins (the peptide
grouping to obtain protein ID's was achieved by the ProteinProphet
algorithm).
[0270] The ID's of these five proteins are shown in FIG. 8.
[0271] The 2 peptides which represent protein 1 also occur in Ig
alpha-1 chain C region, so that the protein ID's 1 and 2 in fact
represent one ID (Ig alpha-1 chain C region).
[0272] The hypothetical protein DKFZP686C02220 is a unique one (in
fact, one peptide is unique, the second one can occur in several
proteins). This protein has typical signatures of immunoglobulins
(regarding InterPro entries), and the second peptide also occurs in
Ig alpha-2 chain C region.
[0273] The proteins 4 and 5 represent one protein ID (haptoglobin
precursor) because both peptides occur also in haptoglobin
precursor, but the corresponding peptides were grouped as
individual proteins by the algorithm used.
[0274] Validation of APO-AIV Fragments Using Western Blotting
[0275] Western blotting has been undertaken to confirm that the
14.6 kDa species was a fragment of APO-AIV.
[0276] Plasma samples were diluted 1:10 with double distilled water
and assayed using a Bradford dye-binding method (diluted samples
permit handling of suitably sized aliquot volumes).
[0277] SDS-PAGE was carried out using 20 .mu.g sample per lane (2
.mu.g if sample is a denatured primary or secondary antibody) on
16% acrylamide gels, 1.5 mm thick, 10 wells (NOVEX) for 1 hr 80 V;
1% hrs 125 V. This was followed by Western Blotting onto
nitrocellulose membrane at 50 V for 11/2 hrs. The blots were probed
with the following antibodies:
[0278] Anti-ApoA-IV (N-terminal specific), Santa Cruz
Biotechnology, Inc.
[0279] Anti-ApoA-IV (C-terminal specific), Santa Cruz
Biotechnology, Inc.
[0280] Both antibodies are affinity purified goat polyclonals
raised against a peptide mapping near the amino (N-terminal) or
carboxy (C-terminal) terminus of ApoA-IV of human origin. These
antibodies were chosen since probing for the N- and C-terminals
should increase the chance of detection of the ApoA-IV protein
and/or fragments.
[0281] Several bands were found that appear to be ApoA-IV specific
and also discriminatory for AD. These bands do not appear in the
secondary antibody-only control blot for control or AD samples.
[0282] Bands 3-6 which are observed in the 10-16 kDa region are
discriminatory for AD bands 3-6, but also appear to align with
bands in the denatured ApoA-IV antibody lanes. It has also been
observed that bands 3-6 are much stronger on blots where the
N-terminal specific anti-ApoA-IV antibody has been used.
[0283] Two other key bands are observed. Band 1 is observed at
approximately 45 kDa and appears to correspond to the full length
mature APO-AIV protein. Band 2 is observed at approximately 28 kDa
and appears to be an N-terminal fragment of APO-AIV.
Complement Factor H Validation.
Methods
Sample Dilution
[0284] Plasma samples were diluted to 1 in 8 in Phosphate buffered
saline (PBS). An equal volume of Laemmli 2.times. sample buffer was
added and then boiled for 10 min until use.
Western Blot
[0285] SDS gel electrophoresis was performed using the Fisher
Scientific 36 well, 1.5 mm gels (all solutions were purchased from
National Diagnostics). Samples were separated on a 10% resolving
gel with a 4% stacking gel (all solutions were purchased from
National Diagnostics). Samples (20 .mu.l) were separated initially
for 30 min at 110V and then for 60 min at 150V until the dye front
just began to enter the running buffer.
[0286] The gel was transferred to PVDF (Amersham Biosciences) using
a Semi-dry transblot (Bio-Rad) for 45 min at 15V. The membrane was
then blocked in 5% milk made in PBS-Tween and probed with
Complement factor H primary antibody (Abcam, UK) overnight at
4.degree. C. The bands were detected with a chemiluminescence
Western detection kit (ECL+, Amersham Biosciences) and the
membranes were scanned using Storm fluorescence scanner (Amersham
Biosciences).
[0287] An immunoreactive band was observed at 139 kDa (CfH) and the
optical density was quantified using the Image Quant (Amersham
Biosciences) software. Analysis was by non-parametric Mann-Whitney
using the SPSS package.
Results
[0288] Western blot data was acquired from plasma from 128 people
with NINCDS-ADRDA probable AD and 78 normal healthy elderly
controls. Cases with AD had a 32% increase in CFH (Mann-Whitney;
table 2)
TABLE-US-00004 TABLE 2 Diagnosis Number Mean CFH SD SEM Controls
128 65.6 65.5 5.8 Probable AD 78 96.0 96.8 11.0
[0289] There was a gender difference with a relatively higher CFH
value in females overall relatives to males (p=0.05). However CFH
was higher in cases with AD relative to controls even when
considering genders separately (p<0.01; table 3)
TABLE-US-00005 TABLE 3 Mean Females only Number CFH SEM Controls 78
73.0 8.9 Probable AD 64 102.7 13.0 Total 142 86.4 7.7
[0290] A receiver operator curve (ROC) analysis showed that CFH
performs better than chance as a diagnostic test.
[0291] The references mentioned herein are all expressly
incorporated by reference.
REFERENCES
[0292] Andreasen, N., C. Hesse, et al. (1999). "Cerebrospinal fluid
beta-amyloid(1-42) in Alzheimer disease: differences between early-
and late-onset Alzheimer disease and stability during the course of
disease." Arch Neurol 56(6): 673-80. [0293] Bosman, G. J., I. G.
Bartholomeus, et al. (1991). "Erythrocyte membrane characteristics
indicate abnormal cellular aging in patients with Alzheimer's
disease." Neurobiol Aging 12(1): 13-8. [0294] Friedland, R. P.
(1993). "Epidemiology, education, and the ecology of Alzheimer's
disease." Neurology 43(2): 246-9. [0295] Ida, N., T. Hartmann, et
al. (1996). "Analysis of heterogeneous A4 peptides in human
cerebrospinal fluid and blood by a newly developed sensitive
Western blot assay." J Biol Chem 271(37): 22908-14. [0296] Kanai,
M., E. Matsubara, et al. (1998). "Longitudinal study of
cerebrospinal fluid levels of tau, A beta1-40, and A beta1-42(43)
in Alzheimer's disease: a study in Japan." Ann Neurol 44(1): 17-26.
[0297] Kawarabayashi, T., L. H. Younkin, et al. (2001).
"Age-dependent changes in brain, CSF, and plasma amyloid (beta)
protein in the Tg2576 transgenic mouse model of Alzheimer's
disease." J Neurosci 21(2): 372-81. [0298] Kosaka, T., M. Imagawa,
et al. (1997). "The beta APP717 Alzheimer mutation increases the
percentage of plasma amyloid-beta protein ending at A beta42(43)."
Neurology 48(3): 741-5. [0299] Kuo, Y. M., T. A. Kokjohn, et al.
(2000). "Elevated abeta42 in skeletal muscle of Alzheimer disease
patients suggests peripheral alterations of AbetaPP metabolism." Am
J Pathol 156(3): 797-805. [0300] Lindner, M. D., D. D. Gordon, et
al. (1993). "Increased levels of truncated nerve growth factor
receptor in urine of mildly demented patients with Alzheimer's
disease." Arch Neurol 50(10): 1054-60. [0301] Pirttila, T., S.
Mattinen, et al. (1992). "The decrease of CD8-positive lymphocytes
in Alzheimer's disease." J Neurol Sci 107(2): 160-5. [0302] Rocca,
W. A., A. Hofman, et al. (1991). "Frequency and distribution of
Alzheimer's disease in Europe: a collaborative study of 1980-1990
prevalence findings. The EURODEM-Prevalence Research Group." Ann
Neurol 30(3): 381-90. [0303] Scheuner, D., C. Eckman, et al.
(1996). "Secreted amyloid beta-protein similar to that in the
senile plaques of Alzheimer's disease is increased in vivo by the
presenilin 1 and 2 and APP mutations linked to familial Alzheimer's
disease." Nat Med 2(8): 864-70. [0304] Ueno, I., T. Sakai, et al.
(2000). "Analysis of blood plasma proteins in patients with
Alzheimer's disease by two-dimensional electrophoresis, sequence
homology and immunodetection." Electrophoresis 21(9): 1832-45.
Sequence CWU 1
1
91396PRTHomo Sapiens 1Met Phe Leu Lys Ala Val Val Leu Thr Leu Ala
Leu Val Ala Val Ala1 5 10 15Gly Ala Arg Ala Glu Val Ser Ala Asp Gln
Val Ala Thr Val Met Trp 20 25 30Asp Tyr Phe Ser Gln Leu Ser Asn Asn
Ala Lys Glu Ala Val Glu His 35 40 45Leu Gln Lys Ser Glu Leu Thr Gln
Gln Leu Asn Ala Leu Phe Gln Asp 50 55 60Lys Leu Gly Glu Val Asn Thr
Tyr Ala Gly Asp Leu Gln Lys Lys Leu65 70 75 80Val Pro Phe Ala Thr
Glu Leu His Glu Arg Leu Ala Lys Asp Ser Glu 85 90 95Lys Leu Lys Glu
Glu Ile Gly Lys Glu Leu Glu Glu Leu Arg Ala Arg 100 105 110Leu Leu
Pro His Ala Asn Glu Val Ser Gln Lys Ile Gly Asp Asn Leu 115 120
125Arg Glu Leu Gln Gln Arg Leu Glu Pro Tyr Ala Asp Gln Leu Arg Thr
130 135 140Gln Val Asn Thr Gln Ala Glu Gln Leu Arg Arg Gln Leu Thr
Pro Tyr145 150 155 160Ala Gln Arg Met Glu Arg Val Leu Arg Glu Asn
Ala Asp Ser Leu Gln 165 170 175Ala Ser Leu Arg Pro His Ala Asp Glu
Leu Lys Ala Lys Ile Asp Gln 180 185 190Asn Val Glu Glu Leu Lys Gly
Arg Leu Thr Pro Tyr Ala Asp Glu Phe 195 200 205Lys Val Lys Ile Asp
Gln Thr Val Glu Glu Leu Arg Arg Ser Leu Ala 210 215 220Pro Tyr Ala
Gln Asp Thr Gln Glu Lys Leu Asn His Gln Leu Glu Gly225 230 235
240Leu Thr Phe Gln Met Lys Lys Asn Ala Glu Glu Leu Lys Ala Arg Ile
245 250 255Ser Ala Ser Ala Glu Glu Leu Arg Gln Arg Leu Ala Pro Leu
Ala Glu 260 265 270Asp Val Arg Gly Asn Leu Lys Gly Asn Thr Glu Gly
Leu Gln Lys Ser 275 280 285Leu Ala Glu Leu Gly Gly His Leu Asp Gln
Gln Val Glu Glu Phe Arg 290 295 300Arg Arg Val Glu Pro Tyr Gly Glu
Asn Phe Asn Lys Ala Leu Val Gln305 310 315 320Gln Met Glu Gln Leu
Arg Gln Lys Leu Gly Pro His Ala Gly Asp Val 325 330 335Glu Gly His
Leu Ser Phe Leu Glu Lys Asp Leu Arg Asp Lys Val Asn 340 345 350Ser
Phe Phe Ser Thr Phe Lys Glu Lys Glu Ser Gln Asp Lys Thr Leu 355 360
365Ser Leu Pro Glu Leu Glu Gln Gln Gln Glu Gln Gln Gln Glu Gln Gln
370 375 380Gln Glu Gln Val Gln Met Leu Ala Pro Leu Glu Ser385 390
39521744PRTHomo Sapiens 2Met Arg Leu Leu Trp Gly Leu Ile Trp Ala
Ser Ser Phe Phe Thr Leu1 5 10 15Ser Leu Gln Lys Pro Arg Leu Leu Leu
Phe Ser Pro Ser Val Val His 20 25 30Leu Gly Val Pro Leu Ser Val Gly
Val Gln Leu Gln Asp Val Pro Arg 35 40 45Gly Gln Val Val Lys Gly Ser
Val Phe Leu Arg Asn Pro Ser Arg Asn 50 55 60Asn Val Pro Cys Ser Pro
Lys Val Asp Phe Thr Leu Ser Ser Glu Arg65 70 75 80Asp Phe Ala Leu
Leu Ser Leu Gln Val Pro Leu Lys Asp Ala Lys Ser 85 90 95Cys Gly Leu
His Gln Leu Leu Arg Gly Pro Glu Val Gln Leu Val Ala 100 105 110His
Ser Pro Trp Leu Lys Asp Ser Leu Ser Arg Thr Thr Asn Ile Gln 115 120
125Gly Ile Asn Leu Leu Phe Ser Ser Arg Arg Gly His Leu Phe Leu Gln
130 135 140Thr Asp Gln Pro Ile Tyr Asn Pro Gly Gln Arg Val Arg Tyr
Arg Val145 150 155 160Phe Ala Leu Asp Gln Lys Met Arg Pro Ser Thr
Asp Thr Ile Thr Val 165 170 175Met Val Glu Asn Ser His Gly Leu Arg
Val Arg Lys Lys Glu Val Tyr 180 185 190Met Pro Ser Ser Ile Phe Gln
Asp Asp Phe Val Ile Pro Asp Ile Ser 195 200 205Glu Pro Gly Thr Trp
Lys Ile Ser Ala Arg Phe Ser Asp Gly Leu Glu 210 215 220Ser Asn Ser
Ser Thr Gln Phe Glu Val Lys Lys Tyr Val Leu Pro Asn225 230 235
240Phe Glu Val Lys Ile Thr Pro Gly Lys Pro Tyr Ile Leu Thr Val Pro
245 250 255Gly His Leu Asp Glu Met Gln Leu Asp Ile Gln Ala Arg Tyr
Ile Tyr 260 265 270Gly Lys Pro Val Gln Gly Val Ala Tyr Val Arg Phe
Gly Leu Leu Asp 275 280 285Glu Asp Gly Lys Lys Thr Phe Phe Arg Gly
Leu Glu Ser Gln Thr Lys 290 295 300Leu Val Asn Gly Gln Ser His Ile
Ser Leu Ser Lys Ala Glu Phe Gln305 310 315 320Asp Ala Leu Glu Lys
Leu Asn Met Gly Ile Thr Asp Leu Gln Gly Leu 325 330 335Arg Leu Tyr
Val Ala Ala Ala Ile Ile Glu Ser Pro Gly Gly Glu Met 340 345 350Glu
Glu Ala Glu Leu Thr Ser Trp Tyr Phe Val Ser Ser Pro Phe Ser 355 360
365Leu Asp Leu Ser Lys Thr Lys Arg His Leu Val Pro Gly Ala Pro Phe
370 375 380Leu Leu Gln Ala Leu Val Arg Glu Met Ser Gly Ser Pro Ala
Ser Gly385 390 395 400Ile Pro Val Lys Val Ser Ala Thr Val Ser Ser
Pro Gly Ser Val Pro 405 410 415Glu Val Gln Asp Ile Gln Gln Asn Thr
Asp Gly Ser Gly Gln Val Ser 420 425 430Ile Pro Ile Ile Ile Pro Gln
Thr Ile Ser Glu Leu Gln Leu Ser Val 435 440 445Ser Ala Gly Ser Pro
His Pro Ala Ile Ala Arg Leu Thr Val Ala Ala 450 455 460Pro Pro Ser
Gly Gly Pro Gly Phe Leu Ser Ile Glu Arg Pro Asp Ser465 470 475
480Arg Pro Pro Arg Val Gly Asp Thr Leu Asn Leu Asn Leu Arg Ala Val
485 490 495Gly Ser Gly Ala Thr Phe Ser His Tyr Tyr Tyr Met Ile Leu
Ser Arg 500 505 510Gly Gln Ile Val Phe Met Asn Arg Glu Pro Lys Arg
Thr Leu Thr Ser 515 520 525Val Ser Val Phe Val Asp His His Leu Ala
Pro Ser Phe Tyr Phe Val 530 535 540Ala Phe Tyr Tyr His Gly Asp His
Pro Val Ala Asn Ser Leu Arg Val545 550 555 560Asp Val Gln Ala Gly
Ala Cys Glu Gly Lys Leu Glu Leu Ser Val Asp 565 570 575Gly Ala Lys
Gln Tyr Arg Asn Gly Glu Ser Val Lys Leu His Leu Glu 580 585 590Thr
Asp Ser Leu Ala Leu Val Ala Leu Gly Ala Leu Asp Thr Ala Leu 595 600
605Tyr Ala Ala Gly Ser Lys Ser His Lys Pro Leu Asn Met Gly Lys Val
610 615 620Phe Glu Ala Met Asn Ser Tyr Asp Leu Gly Cys Gly Pro Gly
Gly Gly625 630 635 640Asp Ser Ala Leu Gln Val Phe Gln Ala Ala Gly
Leu Ala Phe Ser Asp 645 650 655Gly Asp Gln Trp Thr Leu Ser Arg Lys
Arg Leu Ser Cys Pro Lys Glu 660 665 670Lys Thr Thr Arg Lys Lys Arg
Asn Val Asn Phe Gln Lys Ala Ile Asn 675 680 685Glu Lys Leu Gly Gln
Tyr Ala Ser Pro Thr Ala Lys Arg Cys Cys Gln 690 695 700Asp Gly Val
Thr Arg Leu Pro Met Met Arg Ser Cys Glu Gln Arg Ala705 710 715
720Ala Arg Val Gln Gln Pro Asp Cys Arg Glu Pro Phe Leu Ser Cys Cys
725 730 735Gln Phe Ala Glu Ser Leu Arg Lys Lys Ser Arg Asp Lys Gly
Gln Ala 740 745 750Gly Leu Gln Arg Ala Leu Glu Ile Leu Gln Glu Glu
Asp Leu Ile Asp 755 760 765Glu Asp Asp Ile Pro Val Arg Ser Phe Phe
Pro Glu Asn Trp Leu Trp 770 775 780Arg Val Glu Thr Val Asp Arg Phe
Gln Ile Leu Thr Leu Trp Leu Pro785 790 795 800Asp Ser Leu Thr Thr
Trp Glu Ile His Gly Leu Ser Leu Ser Lys Thr 805 810 815Lys Gly Leu
Cys Val Ala Thr Pro Val Gln Leu Arg Val Phe Arg Glu 820 825 830Phe
His Leu His Leu Arg Leu Pro Met Ser Val Arg Arg Phe Glu Gln 835 840
845Leu Glu Leu Arg Pro Val Leu Tyr Asn Tyr Leu Asp Lys Asn Leu Thr
850 855 860Val Ser Val His Val Ser Pro Val Glu Gly Leu Cys Leu Ala
Gly Gly865 870 875 880Gly Gly Leu Ala Gln Gln Val Leu Val Pro Ala
Gly Ser Ala Arg Pro 885 890 895Val Ala Phe Ser Val Val Pro Thr Ala
Ala Ala Ala Val Ser Leu Lys 900 905 910Val Val Ala Arg Gly Ser Phe
Glu Phe Pro Val Gly Asp Ala Val Ser 915 920 925Lys Val Leu Gln Ile
Glu Lys Glu Gly Ala Ile His Arg Glu Glu Leu 930 935 940Val Tyr Glu
Leu Asn Pro Leu Asp His Arg Gly Arg Thr Leu Glu Ile945 950 955
960Pro Gly Asn Ser Asp Pro Asn Met Ile Pro Asp Gly Asp Phe Asn Ser
965 970 975Tyr Val Arg Val Thr Ala Ser Asp Pro Leu Asp Thr Leu Gly
Ser Glu 980 985 990Gly Ala Leu Ser Pro Gly Gly Val Ala Ser Leu Leu
Arg Leu Pro Arg 995 1000 1005Gly Cys Gly Glu Gln Thr Met Ile Tyr
Leu Ala Pro Thr Leu Ala Ala 1010 1015 1020Ser Arg Tyr Leu Asp Lys
Thr Glu Gln Trp Ser Thr Leu Pro Pro Glu1025 1030 1035 1040Thr Lys
Asp His Ala Val Asp Leu Ile Gln Lys Gly Tyr Met Arg Ile 1045 1050
1055Gln Gln Phe Arg Lys Ala Asp Gly Ser Tyr Ala Ala Trp Leu Ser Arg
1060 1065 1070Asp Ser Ser Thr Trp Leu Thr Ala Phe Val Leu Lys Val
Leu Ser Leu 1075 1080 1085Ala Gln Glu Gln Val Gly Gly Ser Pro Glu
Lys Leu Gln Glu Thr Ser 1090 1095 1100Asn Trp Leu Leu Ser Gln Gln
Gln Ala Asp Gly Ser Phe Gln Asp Pro1105 1110 1115 1120Cys Pro Val
Leu Asp Arg Ser Met Gln Gly Gly Leu Val Gly Asn Asp 1125 1130
1135Glu Thr Val Ala Leu Thr Ala Phe Val Thr Ile Ala Leu His His Gly
1140 1145 1150Leu Ala Val Phe Gln Asp Glu Gly Ala Glu Pro Leu Lys
Gln Arg Val 1155 1160 1165Glu Ala Ser Ile Ser Lys Ala Asn Ser Phe
Leu Gly Glu Lys Ala Ser 1170 1175 1180Ala Gly Leu Leu Gly Ala His
Ala Ala Ala Ile Thr Ala Tyr Ala Leu1185 1190 1195 1200Ser Leu Thr
Lys Ala Pro Val Asp Leu Leu Gly Val Ala His Asn Asn 1205 1210
1215Leu Met Ala Met Ala Gln Glu Thr Gly Asp Asn Leu Tyr Trp Gly Ser
1220 1225 1230Val Thr Gly Ser Gln Ser Asn Ala Val Ser Pro Thr Pro
Ala Pro Arg 1235 1240 1245Asn Pro Ser Asp Pro Met Pro Gln Ala Pro
Ala Leu Trp Ile Glu Thr 1250 1255 1260Thr Ala Tyr Ala Leu Leu His
Leu Leu Leu His Glu Gly Lys Ala Glu1265 1270 1275 1280Met Ala Asp
Gln Ala Ser Ala Trp Leu Thr Arg Gln Gly Ser Phe Gln 1285 1290
1295Gly Gly Phe Arg Ser Thr Gln Asp Thr Val Ile Ala Leu Asp Ala Leu
1300 1305 1310Ser Ala Tyr Trp Ile Ala Ser His Thr Thr Glu Glu Arg
Gly Leu Asn 1315 1320 1325Val Thr Leu Ser Ser Thr Gly Arg Asn Gly
Phe Lys Ser His Ala Leu 1330 1335 1340Gln Leu Asn Asn Arg Gln Ile
Arg Gly Leu Glu Glu Glu Leu Gln Phe1345 1350 1355 1360Ser Leu Gly
Ser Lys Ile Asn Val Lys Val Gly Gly Asn Ser Lys Gly 1365 1370
1375Thr Leu Lys Val Leu Arg Thr Tyr Asn Val Leu Asp Met Lys Asn Thr
1380 1385 1390Thr Cys Gln Asp Leu Gln Ile Glu Val Thr Val Lys Gly
His Val Glu 1395 1400 1405Tyr Thr Met Glu Ala Asn Glu Asp Tyr Glu
Asp Tyr Glu Tyr Asp Glu 1410 1415 1420Leu Pro Ala Lys Asp Asp Pro
Asp Ala Pro Leu Gln Pro Val Thr Pro1425 1430 1435 1440Leu Gln Leu
Phe Glu Gly Arg Arg Asn Arg Arg Arg Arg Glu Ala Pro 1445 1450
1455Lys Val Val Glu Glu Gln Glu Ser Arg Val His Tyr Thr Val Cys Ile
1460 1465 1470Trp Arg Asn Gly Lys Val Gly Leu Ser Gly Met Ala Ile
Ala Asp Val 1475 1480 1485Thr Leu Leu Ser Gly Phe His Ala Leu Arg
Ala Asp Leu Glu Lys Leu 1490 1495 1500Thr Ser Leu Ser Asp Arg Tyr
Val Ser His Phe Glu Thr Glu Gly Pro1505 1510 1515 1520His Val Leu
Leu Tyr Phe Asp Ser Val Pro Thr Ser Arg Glu Cys Val 1525 1530
1535Gly Phe Glu Ala Val Gln Glu Val Pro Val Gly Leu Val Gln Pro Ala
1540 1545 1550Ser Ala Thr Leu Tyr Asp Tyr Tyr Asn Pro Glu Arg Arg
Cys Ser Val 1555 1560 1565Phe Tyr Gly Ala Pro Ser Lys Ser Arg Leu
Leu Ala Thr Leu Cys Ser 1570 1575 1580Ala Glu Val Cys Gln Cys Ala
Glu Gly Lys Cys Pro Arg Gln Arg Arg1585 1590 1595 1600Ala Leu Glu
Arg Gly Leu Gln Asp Glu Asp Gly Tyr Arg Met Lys Phe 1605 1610
1615Ala Cys Tyr Tyr Pro Arg Val Glu Tyr Gly Phe Gln Val Lys Val Leu
1620 1625 1630Arg Glu Asp Ser Arg Ala Ala Phe Arg Leu Phe Glu Thr
Lys Ile Thr 1635 1640 1645Gln Val Leu His Phe Thr Lys Asp Val Lys
Ala Ala Ala Asn Gln Met 1650 1655 1660Arg Asn Phe Leu Val Arg Ala
Ser Cys Arg Leu Arg Leu Glu Pro Gly1665 1670 1675 1680Lys Glu Tyr
Leu Ile Met Gly Leu Asp Gly Ala Thr Tyr Asp Leu Glu 1685 1690
1695Gly His Pro Gln Tyr Leu Leu Asp Ser Asn Ser Trp Ile Glu Glu Met
1700 1705 1710Pro Ser Glu Arg Leu Cys Arg Ser Thr Arg Gln Arg Ala
Ala Cys Ala 1715 1720 1725Gln Leu Asn Asp Phe Leu Gln Glu Tyr Gly
Thr Gln Gly Cys Gln Val 1730 1735 174031474PRTHomo Sapiens 3Met Gly
Lys Asn Lys Leu Leu His Pro Ser Leu Val Leu Leu Leu Leu1 5 10 15Val
Leu Leu Pro Thr Asp Ala Ser Val Ser Gly Lys Pro Gln Tyr Met 20 25
30Val Leu Val Pro Ser Leu Leu His Thr Glu Thr Thr Glu Lys Gly Cys
35 40 45Val Leu Leu Ser Tyr Leu Asn Glu Thr Val Thr Val Ser Ala Ser
Leu 50 55 60Glu Ser Val Arg Gly Asn Arg Ser Leu Phe Thr Asp Leu Glu
Ala Glu65 70 75 80Asn Asp Val Leu His Cys Val Ala Phe Ala Val Pro
Lys Ser Ser Ser 85 90 95Asn Glu Glu Val Met Phe Leu Thr Val Gln Val
Lys Gly Pro Thr Gln 100 105 110Glu Phe Lys Lys Arg Thr Thr Val Met
Val Lys Asn Glu Asp Ser Leu 115 120 125Val Phe Val Gln Thr Asp Lys
Ser Ile Tyr Lys Pro Gly Gln Thr Val 130 135 140Lys Phe Arg Val Val
Ser Met Asp Glu Asn Phe His Pro Leu Asn Glu145 150 155 160Leu Ile
Pro Leu Val Tyr Ile Gln Asp Pro Lys Gly Asn Arg Ile Ala 165 170
175Gln Trp Gln Ser Phe Gln Leu Glu Gly Gly Leu Lys Gln Phe Ser Phe
180 185 190Pro Leu Ser Ser Glu Pro Phe Gln Gly Ser Tyr Lys Val Val
Val Gln 195 200 205Lys Lys Ser Gly Gly Arg Thr Glu His Pro Phe Thr
Val Glu Glu Phe 210 215 220Val Leu Pro Lys Phe Glu Val Gln Val Thr
Val Pro Lys Ile Ile Thr225 230 235 240Ile Leu Glu Glu Glu Met Asn
Val Ser Val Cys Gly Leu Tyr Thr Tyr 245 250 255Gly Lys Pro Val Pro
Gly His Val Thr Val Ser Ile Cys Arg Lys Tyr 260 265 270Ser Asp Ala
Ser Asp Cys His Gly Glu Asp Ser Gln Ala Phe Cys Glu 275 280 285Lys
Phe Ser Gly Gln Leu Asn Ser His Gly Cys Phe Tyr Gln Gln Val 290 295
300Lys Thr Lys Val Phe Gln Leu Lys Arg Lys Glu Tyr Glu Met Lys
Leu305 310 315 320His Thr Glu Ala Gln Ile Gln
Glu Glu Gly Thr Val Val Glu Leu Thr 325 330 335Gly Arg Gln Ser Ser
Glu Ile Thr Arg Thr Ile Thr Lys Leu Ser Phe 340 345 350Val Lys Val
Asp Ser His Phe Arg Gln Gly Ile Pro Phe Phe Gly Gln 355 360 365Val
Arg Leu Val Asp Gly Lys Gly Val Pro Ile Pro Asn Lys Val Ile 370 375
380Phe Ile Arg Gly Asn Glu Ala Asn Tyr Tyr Ser Asn Ala Thr Thr
Asp385 390 395 400Glu His Gly Leu Val Gln Phe Ser Ile Asn Thr Thr
Asn Val Met Gly 405 410 415Thr Ser Leu Thr Val Arg Val Asn Tyr Lys
Asp Arg Ser Pro Cys Tyr 420 425 430Gly Tyr Gln Trp Val Ser Glu Glu
His Glu Glu Ala His His Thr Ala 435 440 445Tyr Leu Val Phe Ser Pro
Ser Lys Ser Phe Val His Leu Glu Pro Met 450 455 460Ser His Glu Leu
Pro Cys Gly His Thr Gln Thr Val Gln Ala His Tyr465 470 475 480Ile
Leu Asn Gly Gly Thr Leu Leu Gly Leu Lys Lys Leu Ser Phe Tyr 485 490
495Tyr Leu Ile Met Ala Lys Gly Gly Ile Val Arg Thr Gly Thr His Gly
500 505 510Leu Leu Val Lys Gln Glu Asp Met Lys Gly His Phe Ser Ile
Ser Ile 515 520 525Pro Val Lys Ser Asp Ile Ala Pro Val Ala Arg Leu
Leu Ile Tyr Ala 530 535 540Val Leu Pro Thr Gly Asp Val Ile Gly Asp
Ser Ala Lys Tyr Asp Val545 550 555 560Glu Asn Cys Ile Ala Asn Lys
Val Asp Leu Ser Phe Ser Pro Ser Gln 565 570 575Ser Leu Pro Ala Ser
His Ala His Leu Arg Val Thr Ala Ala Pro Gln 580 585 590Ser Val Cys
Ala Leu Arg Ala Val Asp Gln Ser Val Leu Leu Met Lys 595 600 605Pro
Asp Ala Glu Leu Ser Ala Ser Ser Val Tyr Asn Leu Leu Pro Glu 610 615
620Lys Asp Leu Thr Gly Phe Pro Gly Pro Leu Asn Asp Gln Asp Asp
Glu625 630 635 640Asp Cys Ile Asn Arg His Asn Val Tyr Ile Asn Gly
Ile Thr Tyr Thr 645 650 655Pro Val Ser Ser Thr Asn Glu Lys Asp Met
Tyr Ser Phe Leu Glu Asp 660 665 670Met Gly Leu Lys Ala Phe Thr Asn
Ser Lys Ile Arg Lys Pro Lys Met 675 680 685Cys Pro Gln Leu Gln Gln
Tyr Glu Met His Gly Pro Glu Gly Leu Arg 690 695 700Val Gly Phe Tyr
Glu Ser Asp Val Met Gly Arg Gly His Ala Arg Leu705 710 715 720Val
His Val Glu Glu Pro His Thr Glu Thr Val Arg Lys Tyr Phe Pro 725 730
735Glu Thr Trp Ile Trp Asp Leu Val Val Val Asn Ser Ala Gly Val Ala
740 745 750Glu Val Gly Val Thr Val Pro Asp Thr Ile Thr Glu Trp Lys
Ala Gly 755 760 765Ala Phe Cys Leu Ser Glu Asp Ala Gly Leu Gly Ile
Ser Ser Thr Ala 770 775 780Ser Leu Arg Ala Phe Gln Pro Phe Phe Val
Glu Leu Thr Met Pro Tyr785 790 795 800Ser Val Ile Arg Gly Glu Ala
Phe Thr Leu Lys Ala Thr Val Leu Asn 805 810 815Tyr Leu Pro Lys Cys
Ile Arg Val Ser Val Gln Leu Glu Ala Ser Pro 820 825 830Ala Phe Leu
Ala Val Pro Val Glu Lys Glu Gln Ala Pro His Cys Ile 835 840 845Cys
Ala Asn Gly Arg Gln Thr Val Ser Trp Ala Val Thr Pro Lys Ser 850 855
860Leu Gly Asn Val Asn Phe Thr Val Ser Ala Glu Ala Leu Glu Ser
Gln865 870 875 880Glu Leu Cys Gly Thr Glu Val Pro Ser Val Pro Glu
His Gly Arg Lys 885 890 895Asp Thr Val Ile Lys Pro Leu Leu Val Glu
Pro Glu Gly Leu Glu Lys 900 905 910Glu Thr Thr Phe Asn Ser Leu Leu
Cys Pro Ser Gly Gly Glu Val Ser 915 920 925Glu Glu Leu Ser Leu Lys
Leu Pro Pro Asn Val Val Glu Glu Ser Ala 930 935 940Arg Ala Ser Val
Ser Val Leu Gly Asp Ile Leu Gly Ser Ala Met Gln945 950 955 960Asn
Thr Gln Asn Leu Leu Gln Met Pro Tyr Gly Cys Gly Glu Gln Asn 965 970
975Met Val Leu Phe Ala Pro Asn Ile Tyr Val Leu Asp Tyr Leu Asn Glu
980 985 990Thr Gln Gln Leu Thr Pro Glu Val Lys Ser Lys Ala Ile Gly
Tyr Leu 995 1000 1005Asn Thr Gly Tyr Gln Arg Gln Leu Asn Tyr Lys
His Tyr Asp Gly Ser 1010 1015 1020Tyr Ser Thr Phe Gly Glu Arg Tyr
Gly Arg Asn Gln Gly Asn Thr Trp1025 1030 1035 1040Leu Thr Ala Phe
Val Leu Lys Thr Phe Ala Gln Ala Arg Ala Tyr Ile 1045 1050 1055Phe
Ile Asp Glu Ala His Ile Thr Gln Ala Leu Ile Trp Leu Ser Gln 1060
1065 1070Arg Gln Lys Asp Asn Gly Cys Phe Arg Ser Ser Gly Ser Leu
Leu Asn 1075 1080 1085Asn Ala Ile Lys Gly Gly Val Glu Asp Glu Val
Thr Leu Ser Ala Tyr 1090 1095 1100Ile Thr Ile Ala Leu Leu Glu Ile
Pro Leu Thr Val Thr His Pro Val1105 1110 1115 1120Val Arg Asn Ala
Leu Phe Cys Leu Glu Ser Ala Trp Lys Thr Ala Gln 1125 1130 1135Glu
Gly Asp His Gly Ser His Val Tyr Thr Lys Ala Leu Leu Ala Tyr 1140
1145 1150Ala Phe Ala Leu Ala Gly Asn Gln Asp Lys Arg Lys Glu Val
Leu Lys 1155 1160 1165Ser Leu Asn Glu Glu Ala Val Lys Lys Asp Asn
Ser Val His Trp Glu 1170 1175 1180Arg Pro Gln Lys Pro Lys Ala Pro
Val Gly His Phe Tyr Glu Pro Gln1185 1190 1195 1200Ala Pro Ser Ala
Glu Val Glu Met Thr Ser Tyr Val Leu Leu Ala Tyr 1205 1210 1215Leu
Thr Ala Gln Pro Ala Pro Thr Ser Glu Asp Leu Thr Ser Ala Thr 1220
1225 1230Asn Ile Val Lys Trp Ile Thr Lys Gln Gln Asn Ala Gln Gly
Gly Phe 1235 1240 1245Ser Ser Thr Gln Asp Thr Val Val Ala Leu His
Ala Leu Ser Lys Tyr 1250 1255 1260Gly Ala Ala Thr Phe Thr Arg Thr
Gly Lys Ala Ala Gln Val Thr Ile1265 1270 1275 1280Gln Ser Ser Gly
Thr Phe Ser Ser Lys Phe Gln Val Asp Asn Asn Asn 1285 1290 1295Arg
Leu Leu Leu Gln Gln Val Ser Leu Pro Glu Leu Pro Gly Glu Tyr 1300
1305 1310Ser Met Lys Val Thr Gly Glu Gly Cys Val Tyr Leu Gln Thr
Ser Leu 1315 1320 1325Lys Tyr Asn Ile Leu Pro Glu Lys Glu Glu Phe
Pro Phe Ala Leu Gly 1330 1335 1340Val Gln Thr Leu Pro Gln Thr Cys
Asp Glu Pro Lys Ala His Thr Ser1345 1350 1355 1360Phe Gln Ile Ser
Leu Ser Val Ser Tyr Thr Gly Ser Arg Ser Ala Ser 1365 1370 1375Asn
Met Ala Ile Val Asp Val Lys Met Val Ser Gly Phe Ile Pro Leu 1380
1385 1390Lys Pro Thr Val Lys Met Leu Glu Arg Ser Asn His Val Ser
Arg Thr 1395 1400 1405Glu Val Ser Ser Asn His Val Leu Ile Tyr Leu
Asp Lys Val Ser Asn 1410 1415 1420Gln Thr Leu Ser Leu Phe Phe Thr
Val Leu Gln Asp Val Pro Val Arg1425 1430 1435 1440Asp Leu Lys Pro
Ala Ile Val Lys Val Tyr Asp Tyr Tyr Glu Thr Asp 1445 1450 1455Glu
Phe Ala Ile Ala Glu Tyr Asn Ala Pro Cys Ser Lys Asp Leu Gly 1460
1465 1470Asn Ala4930PRTHomo Sapiens 4Met Lys Pro Pro Arg Pro Val
Arg Thr Cys Ser Lys Val Leu Val Leu1 5 10 15Leu Ser Leu Leu Ala Ile
His Gln Thr Thr Thr Ala Glu Lys Asn Gly 20 25 30Ile Asp Ile Tyr Ser
Leu Thr Val Asp Ser Arg Val Ser Ser Arg Phe 35 40 45Ala His Thr Val
Val Thr Ser Arg Val Val Asn Arg Ala Asn Thr Val 50 55 60Gln Glu Ala
Thr Phe Gln Met Glu Leu Pro Lys Lys Ala Phe Ile Thr65 70 75 80Asn
Phe Ser Met Asn Ile Asp Gly Met Thr Tyr Pro Gly Ile Ile Lys 85 90
95Glu Lys Ala Glu Ala Gln Ala Gln Tyr Ser Ala Ala Val Ala Lys Gly
100 105 110Lys Ser Ala Gly Leu Val Lys Ala Thr Gly Arg Asn Met Glu
Gln Phe 115 120 125Gln Val Ser Val Ser Val Ala Pro Asn Ala Lys Ile
Thr Phe Glu Leu 130 135 140Val Tyr Glu Glu Leu Leu Lys Arg Arg Leu
Gly Val Tyr Glu Leu Leu145 150 155 160Leu Lys Val Arg Pro Gln Gln
Leu Val Lys His Leu Gln Met Asp Ile 165 170 175His Ile Phe Glu Pro
Gln Gly Ile Ser Phe Leu Glu Thr Glu Ser Thr 180 185 190Phe Met Thr
Asn Gln Leu Val Asp Ala Leu Thr Thr Trp Gln Asn Lys 195 200 205Thr
Lys Ala His Ile Arg Phe Lys Pro Thr Leu Ser Gln Gln Gln Lys 210 215
220Ser Pro Glu Gln Gln Glu Thr Val Leu Asp Gly Asn Leu Ile Ile
Arg225 230 235 240Tyr Asp Val Asp Arg Ala Ile Ser Gly Gly Ser Ile
Gln Ile Glu Asn 245 250 255Gly Tyr Phe Val His Tyr Phe Ala Pro Glu
Gly Leu Thr Thr Met Pro 260 265 270Lys Asn Val Val Phe Val Ile Asp
Lys Ser Gly Ser Met Ser Gly Arg 275 280 285Lys Ile Gln Gln Thr Arg
Glu Ala Leu Ile Lys Ile Leu Asp Asp Leu 290 295 300Ser Pro Arg Asp
Gln Phe Asn Leu Ile Val Phe Ser Thr Glu Ala Thr305 310 315 320Gln
Trp Arg Pro Ser Leu Val Pro Ala Ser Ala Glu Asn Val Asn Lys 325 330
335Ala Arg Ser Phe Ala Ala Gly Ile Gln Ala Leu Gly Gly Thr Asn Ile
340 345 350Asn Asp Ala Met Leu Met Ala Val Gln Leu Leu Asp Ser Ser
Asn Gln 355 360 365Glu Glu Arg Leu Pro Glu Gly Ser Val Ser Leu Ile
Ile Leu Leu Thr 370 375 380Asp Gly Asp Pro Thr Val Gly Glu Thr Asn
Pro Arg Ser Ile Gln Asn385 390 395 400Asn Val Arg Glu Ala Val Ser
Gly Arg Tyr Ser Leu Phe Cys Leu Gly 405 410 415Phe Gly Phe Asp Val
Ser Tyr Ala Phe Leu Glu Lys Leu Ala Leu Asp 420 425 430Asn Gly Gly
Leu Ala Arg Arg Ile His Glu Asp Ser Asp Ser Ala Leu 435 440 445Gln
Leu Gln Asp Phe Tyr Gln Glu Val Ala Asn Pro Leu Leu Thr Ala 450 455
460Val Thr Phe Glu Tyr Pro Ser Asn Ala Val Glu Glu Val Thr Gln
Asn465 470 475 480Asn Phe Arg Leu Leu Phe Lys Gly Ser Glu Met Val
Val Ala Gly Lys 485 490 495Leu Gln Asp Arg Gly Pro Asp Val Leu Thr
Ala Thr Val Ser Gly Lys 500 505 510Leu Pro Thr Gln Asn Ile Thr Phe
Gln Thr Glu Ser Ser Val Ala Glu 515 520 525Gln Glu Ala Glu Phe Gln
Ser Pro Lys Tyr Ile Phe His Asn Phe Met 530 535 540Glu Arg Leu Trp
Ala Tyr Leu Thr Ile Gln Gln Leu Leu Glu Gln Thr545 550 555 560Val
Ser Ala Ser Asp Ala Asp Gln Gln Ala Leu Arg Asn Gln Ala Leu 565 570
575Asn Leu Ser Leu Ala Tyr Ser Phe Val Thr Pro Leu Thr Ser Met Val
580 585 590Val Thr Lys Pro Asp Asp Gln Glu Gln Ser Gln Val Ala Glu
Lys Pro 595 600 605Met Glu Gly Glu Ser Arg Asn Arg Asn Val His Ser
Gly Ser Thr Phe 610 615 620Phe Lys Tyr Tyr Leu Gln Gly Ala Lys Ile
Pro Lys Pro Glu Ala Ser625 630 635 640Phe Ser Pro Arg Arg Gly Trp
Asn Arg Gln Ala Gly Ala Ala Gly Ser 645 650 655Arg Met Asn Phe Arg
Pro Gly Val Leu Ser Ser Arg Gln Leu Gly Leu 660 665 670Pro Gly Pro
Pro Asp Val Pro Asp His Ala Ala Tyr His Pro Phe Arg 675 680 685Arg
Leu Ala Ile Leu Pro Ala Ser Ala Pro Pro Ala Thr Ser Asn Pro 690 695
700Asp Pro Ala Val Ser Arg Val Met Asn Met Lys Ile Glu Glu Thr
Thr705 710 715 720Met Thr Thr Gln Thr Pro Ala Pro Ile Gln Ala Pro
Ser Ala Ile Leu 725 730 735Pro Leu Pro Gly Gln Ser Val Glu Arg Leu
Cys Val Asp Pro Arg His 740 745 750Arg Gln Gly Pro Val Asn Leu Leu
Ser Asp Pro Glu Gln Gly Val Glu 755 760 765Val Thr Gly Gln Tyr Glu
Arg Glu Lys Ala Gly Phe Ser Trp Ile Glu 770 775 780Val Thr Phe Lys
Asn Pro Leu Val Trp Val His Ala Ser Pro Glu His785 790 795 800Val
Val Val Thr Arg Asn Arg Arg Ser Ser Ala Tyr Lys Trp Lys Glu 805 810
815Thr Leu Phe Ser Val Met Pro Gly Leu Lys Met Thr Met Asp Lys Thr
820 825 830Gly Leu Leu Leu Leu Ser Asp Pro Asp Lys Val Thr Ile Gly
Leu Leu 835 840 845Phe Trp Asp Gly Arg Gly Glu Gly Leu Arg Leu Leu
Leu Arg Asp Thr 850 855 860Asp Arg Phe Ser Ser His Val Gly Gly Thr
Leu Gly Gln Phe Tyr Gln865 870 875 880Glu Val Leu Trp Gly Ser Pro
Ala Ala Ser Asp Asp Gly Arg Arg Thr 885 890 895Leu Arg Val Gln Gly
Asn Asp His Ser Ala Thr Arg Glu Arg Arg Leu 900 905 910Asp Tyr Gln
Glu Gly Pro Pro Gly Val Glu Ile Ser Cys Trp Ser Val 915 920 925Glu
Leu 93051663PRTHomo Sapiens 5Met Gly Pro Thr Ser Gly Pro Ser Leu
Leu Leu Leu Leu Leu Thr His1 5 10 15Leu Pro Leu Ala Leu Gly Ser Pro
Met Tyr Ser Ile Ile Thr Pro Asn 20 25 30Ile Leu Arg Leu Glu Ser Glu
Glu Thr Met Val Leu Glu Ala His Asp 35 40 45Ala Gln Gly Asp Val Pro
Val Thr Val Thr Val His Asp Phe Pro Gly 50 55 60Lys Lys Leu Val Leu
Ser Ser Glu Lys Thr Val Leu Thr Pro Ala Thr65 70 75 80Asn His Met
Gly Asn Val Thr Phe Thr Ile Pro Ala Asn Arg Glu Phe 85 90 95Lys Ser
Glu Lys Gly Arg Asn Lys Phe Val Thr Val Gln Ala Thr Phe 100 105
110Gly Thr Gln Val Val Glu Lys Val Val Leu Val Ser Leu Gln Ser Gly
115 120 125Tyr Leu Phe Ile Gln Thr Asp Lys Thr Ile Tyr Thr Pro Gly
Ser Thr 130 135 140Val Leu Tyr Arg Ile Phe Thr Val Asn His Lys Leu
Leu Pro Val Gly145 150 155 160Arg Thr Val Met Val Asn Ile Glu Asn
Pro Glu Gly Ile Pro Val Lys 165 170 175Gln Asp Ser Leu Ser Ser Gln
Asn Gln Leu Gly Val Leu Pro Leu Ser 180 185 190Trp Asp Ile Pro Glu
Leu Val Asn Met Gly Gln Trp Lys Ile Arg Ala 195 200 205Tyr Tyr Glu
Asn Ser Pro Gln Gln Val Phe Ser Thr Glu Phe Glu Val 210 215 220Lys
Glu Tyr Val Leu Pro Ser Phe Glu Val Ile Val Glu Pro Thr Glu225 230
235 240Lys Phe Tyr Tyr Ile Tyr Asn Glu Lys Gly Leu Glu Val Thr Ile
Thr 245 250 255Ala Arg Phe Leu Tyr Gly Lys Lys Val Glu Gly Thr Ala
Phe Val Ile 260 265 270Phe Gly Ile Gln Asp Gly Glu Gln Arg Ile Ser
Leu Pro Glu Ser Leu 275 280 285Lys Arg Ile Pro Ile Glu Asp Gly Ser
Gly Glu Val Val Leu Ser Arg 290 295 300Lys Val Leu Leu Asp Gly Val
Gln Asn Leu Arg Ala Glu Asp Leu Val305 310 315 320Gly Lys Ser Leu
Tyr Val Ser Ala Thr Val Ile Leu His Ser Gly Ser 325 330 335Asp Met
Val Gln Ala Glu Arg Ser Gly Ile Pro Ile Val Thr Ser Pro 340 345
350Tyr Gln Ile His Phe Thr Lys Thr Pro Lys Tyr Phe Lys Pro Gly Met
355 360 365Pro Phe Asp Leu Met Val Phe Val Thr Asn Pro Asp Gly Ser
Pro Ala 370 375 380Tyr Arg Val Pro Val
Ala Val Gln Gly Glu Asp Thr Val Gln Ser Leu385 390 395 400Thr Gln
Gly Asp Gly Val Ala Lys Leu Ser Ile Asn Thr His Pro Ser 405 410
415Gln Lys Pro Leu Ser Ile Thr Val Arg Thr Lys Lys Gln Glu Leu Ser
420 425 430Glu Ala Glu Gln Ala Thr Arg Thr Met Gln Ala Leu Pro Tyr
Ser Thr 435 440 445Val Gly Asn Ser Asn Asn Tyr Leu His Leu Ser Val
Leu Arg Thr Glu 450 455 460Leu Arg Pro Gly Glu Thr Leu Asn Val Asn
Phe Leu Leu Arg Met Asp465 470 475 480Arg Ala His Glu Ala Lys Ile
Arg Tyr Tyr Thr Tyr Leu Ile Met Asn 485 490 495Lys Gly Arg Leu Leu
Lys Ala Gly Arg Gln Val Arg Glu Pro Gly Gln 500 505 510Asp Leu Val
Val Leu Pro Leu Ser Ile Thr Thr Asp Phe Ile Pro Ser 515 520 525Phe
Arg Leu Val Ala Tyr Tyr Thr Leu Ile Gly Ala Ser Gly Gln Arg 530 535
540Glu Val Val Ala Asp Ser Val Trp Val Asp Val Lys Asp Ser Cys
Val545 550 555 560Gly Ser Leu Val Val Lys Ser Gly Gln Ser Glu Asp
Arg Gln Pro Val 565 570 575Pro Gly Gln Gln Met Thr Leu Lys Ile Glu
Gly Asp His Gly Ala Arg 580 585 590Val Val Leu Val Ala Val Asp Lys
Gly Val Phe Val Leu Asn Lys Lys 595 600 605Asn Lys Leu Thr Gln Ser
Lys Ile Trp Asp Val Val Glu Lys Ala Asp 610 615 620Ile Gly Cys Thr
Pro Gly Ser Gly Lys Asp Tyr Ala Gly Val Phe Ser625 630 635 640Asp
Ala Gly Leu Thr Phe Thr Ser Ser Ser Gly Gln Gln Thr Ala Gln 645 650
655Arg Ala Glu Leu Gln Cys Pro Gln Pro Ala Ala Arg Arg Arg Arg Ser
660 665 670Val Gln Leu Thr Glu Lys Arg Met Asp Lys Val Gly Lys Tyr
Pro Lys 675 680 685Glu Leu Arg Lys Cys Cys Glu Asp Gly Met Arg Glu
Asn Pro Met Arg 690 695 700Phe Ser Cys Gln Arg Arg Thr Arg Phe Ile
Ser Leu Gly Glu Ala Cys705 710 715 720Lys Lys Val Phe Leu Asp Cys
Cys Asn Tyr Ile Thr Glu Leu Arg Arg 725 730 735Gln His Ala Arg Ala
Ser His Leu Gly Leu Ala Arg Ser Asn Leu Asp 740 745 750Glu Asp Ile
Ile Ala Glu Glu Asn Ile Val Ser Arg Ser Glu Phe Pro 755 760 765Glu
Ser Trp Leu Trp Asn Val Glu Asp Leu Lys Glu Pro Pro Lys Asn 770 775
780Gly Ile Ser Thr Lys Leu Met Asn Ile Phe Leu Lys Asp Ser Ile
Thr785 790 795 800Thr Trp Glu Ile Leu Ala Val Ser Met Ser Asp Lys
Lys Gly Ile Cys 805 810 815Val Ala Asp Pro Phe Glu Val Thr Val Met
Gln Asp Phe Phe Ile Asp 820 825 830Leu Arg Leu Pro Tyr Ser Val Val
Arg Asn Glu Gln Val Glu Ile Arg 835 840 845Ala Val Leu Tyr Asn Tyr
Arg Gln Asn Gln Glu Leu Lys Val Arg Val 850 855 860Glu Leu Leu His
Asn Pro Ala Phe Cys Ser Leu Ala Thr Thr Lys Arg865 870 875 880Arg
His Gln Gln Thr Val Thr Ile Pro Pro Lys Ser Ser Leu Ser Val 885 890
895Pro Tyr Val Ile Val Pro Leu Lys Thr Gly Leu Gln Glu Val Glu Val
900 905 910Lys Ala Ala Val Tyr His His Phe Ile Ser Asp Gly Val Arg
Lys Ser 915 920 925Leu Lys Val Val Pro Glu Gly Ile Arg Met Asn Lys
Thr Val Ala Val 930 935 940Arg Thr Leu Asp Pro Glu Arg Leu Gly Arg
Glu Gly Val Gln Lys Glu945 950 955 960Asp Ile Pro Pro Ala Asp Leu
Ser Asp Gln Val Pro Asp Thr Glu Ser 965 970 975Glu Thr Arg Ile Leu
Leu Gln Gly Thr Pro Val Ala Gln Met Thr Glu 980 985 990Asp Ala Val
Asp Ala Glu Arg Leu Lys His Leu Ile Val Thr Pro Ser 995 1000
1005Gly Cys Gly Glu Gln Asn Met Ile Gly Met Thr Pro Thr Val Ile Ala
1010 1015 1020Val His Tyr Leu Asp Glu Thr Glu Gln Trp Glu Lys Phe
Gly Leu Glu1025 1030 1035 1040Lys Arg Gln Gly Ala Leu Glu Leu Ile
Lys Lys Gly Tyr Thr Gln Gln 1045 1050 1055Leu Ala Phe Arg Gln Pro
Ser Ser Ala Phe Ala Ala Glu Val Lys Arg 1060 1065 1070Ala Pro Ser
Thr Trp Leu Thr Ala Tyr Val Val Lys Val Phe Ser Leu 1075 1080
1085Ala Val Asn Leu Ile Ala Ile Asp Ser Gln Val Leu Cys Gly Ala Val
1090 1095 1100Lys Trp Leu Ile Leu Glu Lys Gln Lys Pro Asp Gly Val
Phe Gln Glu1105 1110 1115 1120Asp Ala Pro Val Ile His Gln Glu Met
Ile Gly Gly Leu Arg Asn Asn 1125 1130 1135Asn Glu Lys Asp Met Ala
Leu Thr Ala Phe Val Leu Ile Ser Leu Gln 1140 1145 1150Glu Ala Lys
Asp Ile Cys Glu Glu Gln Val Asn Ser Leu Pro Gly Ser 1155 1160
1165Ile Thr Lys Ala Gly Asp Phe Leu Glu Ala Asn Tyr Met Asn Leu Gln
1170 1175 1180Arg Ser Tyr Thr Val Ala Ile Ala Gly Tyr Ala Leu Ala
Gln Met Gly1185 1190 1195 1200Arg Leu Lys Gly Pro Leu Leu Asn Lys
Phe Leu Thr Thr Ala Lys Asp 1205 1210 1215Lys Asn Arg Trp Glu Asp
Pro Gly Lys Gln Leu Tyr Asn Val Glu Ala 1220 1225 1230Thr Ser Tyr
Ala Leu Leu Ala Leu Leu Gln Leu Lys Asp Phe Asp Phe 1235 1240
1245Val Pro Pro Val Val Arg Trp Leu Asn Glu Gln Arg Tyr Tyr Gly Gly
1250 1255 1260Gly Tyr Gly Ser Thr Gln Ala Thr Phe Met Val Phe Gln
Ala Leu Ala1265 1270 1275 1280Gln Tyr Gln Lys Asp Ala Pro Asp His
Gln Glu Leu Asn Leu Asp Val 1285 1290 1295Ser Leu Gln Leu Pro Ser
Arg Ser Ser Lys Ile Thr His Arg Ile His 1300 1305 1310Trp Glu Ser
Ala Ser Leu Leu Arg Ser Glu Glu Thr Lys Glu Asn Glu 1315 1320
1325Gly Phe Thr Val Thr Ala Glu Gly Lys Gly Gln Gly Thr Leu Ser Val
1330 1335 1340Val Thr Met Tyr His Ala Lys Ala Lys Asp Gln Leu Thr
Cys Asn Lys1345 1350 1355 1360Phe Asp Leu Lys Val Thr Ile Lys Pro
Ala Pro Glu Thr Glu Lys Arg 1365 1370 1375Pro Gln Asp Ala Lys Asn
Thr Met Ile Leu Glu Ile Cys Thr Arg Tyr 1380 1385 1390Arg Gly Asp
Gln Asp Ala Thr Met Ser Ile Leu Asp Ile Ser Met Met 1395 1400
1405Thr Gly Phe Ala Pro Asp Thr Asp Asp Leu Lys Gln Leu Ala Asn Gly
1410 1415 1420Val Asp Arg Tyr Ile Ser Lys Tyr Glu Leu Asp Lys Ala
Phe Ser Asp1425 1430 1435 1440Arg Asn Thr Leu Ile Ile Tyr Leu Asp
Lys Val Ser His Ser Glu Asp 1445 1450 1455Asp Cys Leu Ala Phe Lys
Val His Gln Tyr Phe Asn Val Glu Leu Ile 1460 1465 1470Gln Pro Gly
Ala Val Lys Val Tyr Ala Tyr Tyr Asn Leu Glu Glu Ser 1475 1480
1485Cys Thr Arg Phe Tyr His Pro Glu Lys Glu Asp Gly Lys Leu Asn Lys
1490 1495 1500Leu Cys Arg Asp Glu Leu Cys Arg Cys Ala Glu Glu Asn
Cys Phe Ile1505 1510 1515 1520Gln Lys Ser Asp Asp Lys Val Thr Leu
Glu Glu Arg Leu Asp Lys Ala 1525 1530 1535Cys Glu Pro Gly Val Asp
Tyr Val Tyr Lys Thr Arg Leu Val Lys Val 1540 1545 1550Gln Leu Ser
Asn Asp Phe Asp Glu Tyr Ile Met Ala Ile Glu Gln Thr 1555 1560
1565Ile Lys Ser Gly Ser Asp Glu Val Gln Val Gly Gln Gln Arg Thr Phe
1570 1575 1580Ile Ser Pro Ile Lys Cys Arg Glu Ala Leu Lys Leu Glu
Glu Lys Lys1585 1590 1595 1600His Tyr Leu Met Trp Gly Leu Ser Ser
Asp Phe Trp Gly Glu Lys Pro 1605 1610 1615Asn Leu Ser Tyr Ile Ile
Gly Lys Asp Thr Trp Val Glu His Trp Pro 1620 1625 1630Glu Glu Asp
Glu Cys Gln Asp Glu Glu Asn Gln Lys Gln Cys Gln Asp 1635 1640
1645Leu Gly Ala Phe Thr Glu Ser Met Val Val Phe Gly Cys Pro Asn
1650 1655 16606449PRTHomo Sapiens 6Met Met Lys Thr Leu Leu Leu Phe
Val Gly Leu Leu Leu Thr Trp Glu1 5 10 15Ser Gly Gln Val Leu Gly Asp
Gln Thr Val Ser Asp Asn Glu Leu Gln 20 25 30Glu Met Ser Asn Gln Gly
Ser Lys Tyr Val Asn Lys Glu Ile Gln Asn 35 40 45Ala Val Asn Gly Val
Lys Gln Ile Lys Thr Leu Ile Glu Lys Thr Asn 50 55 60Glu Glu Arg Lys
Thr Leu Leu Ser Asn Leu Glu Glu Ala Lys Lys Lys65 70 75 80Lys Glu
Asp Ala Leu Asn Glu Thr Arg Glu Ser Glu Thr Lys Leu Lys 85 90 95Glu
Leu Pro Gly Val Cys Asn Glu Thr Met Met Ala Leu Trp Glu Glu 100 105
110Cys Lys Pro Cys Leu Lys Gln Thr Cys Met Lys Phe Tyr Ala Arg Val
115 120 125Cys Arg Ser Gly Ser Gly Leu Val Gly Arg Gln Leu Glu Glu
Phe Leu 130 135 140Asn Gln Ser Ser Pro Phe Tyr Phe Trp Met Asn Gly
Asp Arg Ile Asp145 150 155 160Ser Leu Leu Glu Asn Asp Arg Gln Gln
Thr His Met Leu Asp Val Met 165 170 175Gln Asp His Phe Ser Arg Ala
Ser Ser Ile Ile Asp Glu Leu Phe Gln 180 185 190Asp Arg Phe Phe Thr
Arg Glu Pro Gln Asp Thr Tyr His Tyr Leu Pro 195 200 205Phe Ser Leu
Pro His Arg Arg Pro His Phe Phe Phe Pro Lys Ser Arg 210 215 220Ile
Val Arg Ser Leu Met Pro Phe Ser Pro Tyr Glu Pro Leu Asn Phe225 230
235 240His Ala Met Phe Gln Pro Phe Leu Glu Met Ile His Glu Ala Gln
Gln 245 250 255Ala Met Asp Ile His Phe His Ser Pro Ala Phe Gln His
Pro Pro Thr 260 265 270Glu Phe Ile Arg Glu Gly Asp Asp Asp Arg Thr
Val Cys Arg Glu Ile 275 280 285Arg His Asn Ser Thr Gly Cys Leu Arg
Met Lys Asp Gln Cys Asp Lys 290 295 300Cys Arg Glu Ile Leu Ser Val
Asp Cys Ser Thr Asn Asn Pro Ser Gln305 310 315 320Ala Lys Leu Arg
Arg Glu Leu Asp Glu Ser Leu Gln Val Ala Glu Arg 325 330 335Leu Thr
Arg Lys Tyr Asn Glu Leu Leu Lys Ser Tyr Gln Trp Lys Met 340 345
350Leu Asn Thr Ser Ser Leu Leu Glu Gln Leu Asn Glu Gln Phe Asn Trp
355 360 365Val Ser Arg Leu Ala Asn Leu Thr Gln Gly Glu Asp Gln Tyr
Tyr Leu 370 375 380Arg Val Thr Thr Val Ala Ser His Thr Ser Asp Ser
Asp Val Pro Ser385 390 395 400Gly Val Thr Glu Val Val Val Lys Leu
Phe Asp Ser Asp Pro Ile Thr 405 410 415Val Thr Val Pro Val Glu Val
Ser Arg Lys Asn Pro Lys Phe Met Glu 420 425 430Thr Val Ala Glu Lys
Ala Leu Gln Glu Tyr Arg Lys Lys His Arg Glu 435 440 445Glu
71744PRTHomo Sapiens 7Met Arg Leu Leu Trp Gly Leu Ile Trp Ala Ser
Ser Phe Phe Thr Leu1 5 10 15Ser Leu Gln Lys Pro Arg Leu Leu Leu Phe
Ser Pro Ser Val Val His 20 25 30Leu Gly Val Pro Leu Ser Val Gly Val
Gln Leu Gln Asp Val Pro Arg 35 40 45Gly Gln Val Val Lys Gly Ser Val
Phe Leu Arg Asn Pro Ser Arg Asn 50 55 60Asn Val Pro Cys Ser Pro Lys
Val Asp Phe Thr Leu Ser Ser Glu Arg65 70 75 80Asp Phe Ala Leu Leu
Ser Leu Gln Val Pro Leu Lys Asp Ala Lys Ser 85 90 95Cys Gly Leu His
Gln Leu Leu Arg Gly Pro Glu Val Gln Leu Val Ala 100 105 110His Ser
Pro Trp Leu Lys Asp Ser Leu Ser Arg Thr Thr Asn Ile Gln 115 120
125Gly Ile Asn Leu Leu Phe Ser Ser Arg Arg Gly His Leu Phe Leu Gln
130 135 140Thr Asp Gln Pro Ile Tyr Asn Pro Gly Gln Arg Val Arg Tyr
Arg Val145 150 155 160Phe Ala Leu Asp Gln Lys Met Arg Pro Ser Thr
Asp Thr Ile Thr Val 165 170 175Met Val Glu Asn Ser His Gly Leu Arg
Val Arg Lys Lys Glu Val Tyr 180 185 190Met Pro Ser Ser Ile Phe Gln
Asp Asp Phe Val Ile Pro Asp Ile Ser 195 200 205Glu Pro Gly Thr Trp
Lys Ile Ser Ala Arg Phe Ser Asp Gly Leu Glu 210 215 220Ser Asn Ser
Ser Thr Gln Phe Glu Val Lys Lys Tyr Val Leu Pro Asn225 230 235
240Phe Glu Val Lys Ile Thr Pro Gly Lys Pro Tyr Ile Leu Thr Val Pro
245 250 255Gly His Leu Asp Glu Met Gln Leu Asp Ile Gln Ala Arg Tyr
Ile Tyr 260 265 270Gly Lys Pro Val Gln Gly Val Ala Tyr Val Arg Phe
Gly Leu Leu Asp 275 280 285Glu Asp Gly Lys Lys Thr Phe Phe Arg Gly
Leu Glu Ser Gln Thr Lys 290 295 300Leu Val Asn Gly Gln Ser His Ile
Ser Leu Ser Lys Ala Glu Phe Gln305 310 315 320Asp Ala Leu Glu Lys
Leu Asn Met Gly Ile Thr Asp Leu Gln Gly Leu 325 330 335Arg Leu Tyr
Val Ala Ala Ala Ile Ile Glu Ser Pro Gly Gly Glu Met 340 345 350Glu
Glu Ala Glu Leu Thr Ser Trp Tyr Phe Val Ser Ser Pro Phe Ser 355 360
365Leu Asp Leu Ser Lys Thr Lys Arg His Leu Val Pro Gly Ala Pro Phe
370 375 380Leu Leu Gln Ala Leu Val Arg Glu Met Ser Gly Ser Pro Ala
Ser Gly385 390 395 400Ile Pro Val Lys Val Ser Ala Thr Val Ser Ser
Pro Gly Ser Val Pro 405 410 415Glu Val Gln Asp Ile Gln Gln Asn Thr
Asp Gly Ser Gly Gln Val Ser 420 425 430Ile Pro Ile Ile Ile Pro Gln
Thr Ile Ser Glu Leu Gln Leu Ser Val 435 440 445Ser Ala Gly Ser Pro
His Pro Ala Ile Ala Arg Leu Thr Val Ala Ala 450 455 460Pro Pro Ser
Gly Gly Pro Gly Phe Leu Ser Ile Glu Arg Pro Asp Ser465 470 475
480Arg Pro Pro Arg Val Gly Asp Thr Leu Asn Leu Asn Leu Arg Ala Val
485 490 495Gly Ser Gly Ala Thr Phe Ser His Tyr Tyr Tyr Met Ile Leu
Ser Arg 500 505 510Gly Gln Ile Val Phe Met Asn Arg Glu Pro Lys Arg
Thr Leu Thr Ser 515 520 525Val Ser Val Phe Val Asp His His Leu Ala
Pro Ser Phe Tyr Phe Val 530 535 540Ala Phe Tyr Tyr His Gly Asp His
Pro Val Ala Asn Ser Leu Arg Val545 550 555 560Asp Val Gln Ala Gly
Ala Cys Glu Gly Lys Leu Glu Leu Ser Val Asp 565 570 575Gly Ala Lys
Gln Tyr Arg Asn Gly Glu Ser Val Lys Leu His Leu Glu 580 585 590Thr
Asp Ser Leu Ala Leu Val Ala Leu Gly Ala Leu Asp Thr Ala Leu 595 600
605Tyr Ala Ala Gly Ser Lys Ser His Lys Pro Leu Asn Met Gly Lys Val
610 615 620Phe Glu Ala Met Asn Ser Tyr Asp Leu Gly Cys Gly Pro Gly
Gly Gly625 630 635 640Asp Ser Ala Leu Gln Val Phe Gln Ala Ala Gly
Leu Ala Phe Ser Asp 645 650 655Gly Asp Gln Trp Thr Leu Ser Arg Lys
Arg Leu Ser Cys Pro Lys Glu 660 665 670Lys Thr Thr Arg Lys Lys Arg
Asn Val Asn Phe Gln Lys Ala Ile Asn 675 680 685Glu Lys Leu Gly Gln
Tyr Ala Ser Pro Thr Ala Lys Arg Cys Cys Gln 690 695 700Asp Gly Val
Thr Arg Leu Pro Met Met Arg Ser Cys Glu Gln Arg Ala705 710 715
720Ala Arg Val Gln Gln Pro Asp Cys Arg Glu Pro Phe Leu Ser Cys Cys
725 730 735Gln Phe Ala
Glu Ser Leu Arg Lys Lys Ser Arg Asp Lys Gly Gln Ala 740 745 750Gly
Leu Gln Arg Ala Leu Glu Ile Leu Gln Glu Glu Asp Leu Ile Asp 755 760
765Glu Asp Asp Ile Pro Val Arg Ser Phe Phe Pro Glu Asn Trp Leu Trp
770 775 780Arg Val Glu Thr Val Asp Arg Phe Gln Ile Leu Thr Leu Trp
Leu Pro785 790 795 800Asp Ser Leu Thr Thr Trp Glu Ile His Gly Leu
Ser Leu Ser Lys Thr 805 810 815Lys Gly Leu Cys Val Ala Thr Pro Val
Gln Leu Arg Val Phe Arg Glu 820 825 830Phe His Leu His Leu Arg Leu
Pro Met Ser Val Arg Arg Phe Glu Gln 835 840 845Leu Glu Leu Arg Pro
Val Leu Tyr Asn Tyr Leu Asp Lys Asn Leu Thr 850 855 860Val Ser Val
His Val Ser Pro Val Glu Gly Leu Cys Leu Ala Gly Gly865 870 875
880Gly Gly Leu Ala Gln Gln Val Leu Val Pro Ala Gly Ser Ala Arg Pro
885 890 895Val Ala Phe Ser Val Val Pro Thr Ala Ala Ala Ala Val Ser
Leu Lys 900 905 910Val Val Ala Arg Gly Ser Phe Glu Phe Pro Val Gly
Asp Ala Val Ser 915 920 925Lys Val Leu Gln Ile Glu Lys Glu Gly Ala
Ile His Arg Glu Glu Leu 930 935 940Val Tyr Glu Leu Asn Pro Leu Asp
His Arg Gly Arg Thr Leu Glu Ile945 950 955 960Pro Gly Asn Ser Asp
Pro Asn Met Ile Pro Asp Gly Asp Glu Asn Ser 965 970 975Tyr Val Arg
Val Thr Ala Ser Asp Pro Leu Asp Thr Leu Gly Ser Glu 980 985 990Gly
Ala Leu Ser Pro Gly Gly Val Ala Ser Leu Leu Arg Leu Pro Arg 995
1000 1005Gly Cys Gly Glu Gln Thr Met Ile Tyr Leu Ala Pro Thr Leu
Ala Ala 1010 1015 1020Ser Arg Tyr Leu Asp Lys Thr Glu Gln Trp Ser
Thr Leu Pro Pro Glu1025 1030 1035 1040Thr Lys Asp His Ala Val Asp
Leu Ile Gln Lys Gly Tyr Met Arg Ile 1045 1050 1055Gln Gln Phe Arg
Lys Ala Asp Gly Ser Tyr Ala Ala Trp Leu Ser Arg 1060 1065 1070Asp
Ser Ser Thr Trp Leu Thr Ala Phe Val Leu Lys Val Leu Ser Leu 1075
1080 1085Ala Gln Glu Gln Val Gly Gly Ser Pro Glu Lys Leu Gln Glu
Thr Ser 1090 1095 1100Asn Trp Leu Leu Ser Gln Gln Gln Ala Asp Gly
Ser Phe Gln Asp Pro1105 1110 1115 1120Cys Pro Val Leu Asp Arg Ser
Met Gln Gly Gly Leu Val Gly Asn Asp 1125 1130 1135Glu Thr Val Ala
Leu Thr Ala Phe Val Thr Ile Ala Leu His His Gly 1140 1145 1150Leu
Ala Val Phe Gln Asp Glu Gly Ala Glu Pro Leu Lys Gln Arg Val 1155
1160 1165Glu Ala Ser Ile Ser Lys Ala Asn Ser Phe Leu Gly Glu Lys
Ala Ser 1170 1175 1180Ala Gly Leu Leu Gly Ala His Ala Ala Ala Ile
Thr Ala Tyr Ala Leu1185 1190 1195 1200Ser Leu Thr Lys Ala Pro Val
Asp Leu Leu Gly Val Ala His Asn Asn 1205 1210 1215Leu Met Ala Met
Ala Gln Glu Thr Gly Asp Asn Leu Tyr Trp Gly Ser 1220 1225 1230Val
Thr Gly Ser Gln Ser Asn Ala Val Ser Pro Thr Pro Ala Pro Arg 1235
1240 1245Asn Pro Ser Asp Pro Met Pro Gln Ala Pro Ala Leu Trp Ile
Glu Thr 1250 1255 1260Thr Ala Tyr Ala Leu Leu His Leu Leu Leu His
Glu Gly Lys Ala Glu1265 1270 1275 1280Met Ala Asp Gln Ala Ser Ala
Trp Leu Thr Arg Gln Gly Ser Phe Gln 1285 1290 1295Gly Gly Glu Arg
Ser Thr Gln Asp Thr Val Ile Ala Leu Asp Ala Leu 1300 1305 1310Ser
Ala Tyr Trp Ile Ala Ser His Thr Thr Glu Glu Arg Gly Leu Asn 1315
1320 1325Val Thr Leu Ser Ser Thr Gly Arg Asn Gly Phe Lys Ser His
Ala Leu 1330 1335 1340Gln Leu Asn Asn Arg Gln Ile Arg Gly Leu Glu
Glu Glu Leu Gln Phe1345 1350 1355 1360Ser Leu Gly Ser Lys Ile Asn
Val Lys Val Gly Gly Asn Ser Lys Gly 1365 1370 1375Thr Leu Lys Val
Leu Arg Thr Tyr Asn Val Leu Asp Met Lys Asn Thr 1380 1385 1390Thr
Cys Gln Asp Leu Gln Ile Glu Val Thr Val Lys Gly His Val Glu 1395
1400 1405Tyr Thr Met Glu Ala Asn Glu Asp Tyr Glu Asp Tyr Glu Tyr
Asp Glu 1410 1415 1420Leu Pro Ala Lys Asp Asp Pro Asp Ala Pro Leu
Gln Pro Val Thr Pro1425 1430 1435 1440Leu Gln Leu Phe Glu Gly Arg
Arg Asn Arg Arg Arg Arg Glu Ala Pro 1445 1450 1455Lys Val Val Glu
Glu Gln Glu Ser Arg Val His Tyr Thr Val Cys Ile 1460 1465 1470Trp
Arg Asn Gly Lys Val Gly Leu Ser Gly Met Ala Ile Ala Asp Val 1475
1480 1485Thr Leu Leu Ser Gly Phe His Ala Leu Arg Ala Asp Leu Glu
Lys Leu 1490 1495 1500Thr Ser Leu Ser Asp Arg Tyr Val Ser His Phe
Glu Thr Glu Gly Pro1505 1510 1515 1520His Val Leu Leu Tyr Phe Asp
Ser Val Pro Thr Ser Arg Glu Cys Val 1525 1530 1535Gly Phe Glu Ala
Val Gln Glu Val Pro Val Gly Leu Val Gln Pro Ala 1540 1545 1550Ser
Ala Thr Leu Tyr Asp Tyr Tyr Asn Pro Glu Arg Arg Cys Ser Val 1555
1560 1565Phe Tyr Gly Ala Pro Ser Lys Ser Arg Leu Leu Ala Thr Leu
Cys Ser 1570 1575 1580Ala Glu Val Cys Gln Cys Ala Glu Gly Lys Cys
Pro Arg Gln Arg Arg1585 1590 1595 1600Ala Leu Glu Arg Gly Leu Gln
Asp Glu Asp Gly Tyr Arg Met Lys Phe 1605 1610 1615Ala Cys Tyr Tyr
Pro Arg Val Glu Tyr Gly Phe Gln Val Lys Val Leu 1620 1625 1630Arg
Glu Asp Ser Arg Ala Ala Phe Arg Leu Phe Glu Thr Lys Ile Thr 1635
1640 1645Gln Val Leu His Phe Thr Lys Asp Val Lys Ala Ala Ala Asn
Gln Met 1650 1655 1660Arg Asn Phe Leu Val Arg Ala Ser Cys Arg Leu
Arg Leu Glu Pro Gly1665 1670 1675 1680Lys Glu Tyr Leu Ile Met Gly
Leu Asp Gly Ala Thr Tyr Asp Leu Glu 1685 1690 1695Gly His Pro Gln
Tyr Leu Leu Asp Ser Asn Ser Trp Ile Glu Glu Met 1700 1705 1710Pro
Ser Glu Arg Leu Cys Arg Ser Thr Arg Gln Arg Ala Ala Cys Ala 1715
1720 1725Gln Leu Asn Asp Phe Leu Gln Glu Tyr Gly Thr Gln Gly Cys
Gln Val 1730 1735 17408375PRTHomo Sapiens 8Met Glu Glu Glu Ile Ala
Ala Leu Val Ile Asp Asn Gly Ser Gly Met1 5 10 15Cys Lys Ala Gly Phe
Ala Gly Asp Asp Ala Pro Arg Ala Val Phe Pro 20 25 30Ser Ile Val Gly
Arg Pro Arg His Gln Gly Val Met Val Gly Met Gly 35 40 45Gln Lys Asp
Ser Tyr Val Gly Asp Glu Ala Gln Ser Lys Arg Gly Ile 50 55 60Leu Thr
Leu Lys Tyr Pro Ile Glu His Gly Ile Val Thr Asn Trp Asp65 70 75
80Asp Met Glu Lys Ile Trp His His Thr Phe Tyr Asn Glu Leu Arg Val
85 90 95Ala Pro Glu Glu His Pro Val Leu Leu Thr Glu Ala Pro Leu Asn
Pro 100 105 110Lys Ala Asn Arg Glu Lys Met Thr Gln Ile Met Phe Glu
Thr Phe Asn 115 120 125Thr Pro Ala Met Tyr Val Ala Ile Gln Ala Val
Leu Ser Leu Tyr Ala 130 135 140Ser Gly Arg Thr Thr Gly Ile Val Met
Asp Ser Gly Asp Gly Val Thr145 150 155 160His Thr Val Pro Ile Tyr
Glu Gly Tyr Ala Leu Pro His Ala Ile Leu 165 170 175Arg Leu Asp Leu
Ala Gly Arg Asp Leu Thr Asp Tyr Leu Met Lys Ile 180 185 190Leu Thr
Glu Arg Gly Tyr Ser Phe Thr Thr Thr Ala Glu Arg Glu Ile 195 200
205Val Arg Asp Ile Lys Glu Lys Leu Cys Tyr Val Ala Leu Asp Phe Glu
210 215 220Gln Glu Met Ala Thr Ala Ala Ser Ser Ser Ser Leu Glu Lys
Ser Tyr225 230 235 240Glu Leu Pro Asp Gly Gln Val Ile Thr Ile Gly
Asn Glu Arg Phe Arg 245 250 255Cys Pro Glu Ala Leu Phe Gln Pro Ser
Phe Leu Gly Met Glu Ser Cys 260 265 270Gly Ile His Glu Thr Thr Phe
Asn Ser Ile Met Lys Cys Asp Val Asp 275 280 285Ile Arg Lys Asp Leu
Tyr Ala Asn Thr Val Leu Ser Gly Gly Thr Thr 290 295 300Met Tyr Pro
Gly Ile Ala Asp Arg Met Gln Lys Glu Ile Thr Ala Leu305 310 315
320Ala Pro Ser Thr Met Lys Ile Lys Ile Ile Ala Pro Pro Glu Arg Lys
325 330 335Tyr Ser Val Trp Ile Gly Gly Ser Ile Leu Ala Ser Leu Ser
Thr Phe 340 345 350Gln Gln Met Trp Ile Ser Lys Gln Glu Tyr Asp Glu
Ser Gly Pro Ser 355 360 365Ile Val His Arg Lys Cys Phe 370
3759406PRTHomo Sapiens 9Met Ser Ala Leu Gly Ala Val Ile Ala Leu Leu
Leu Trp Gly Gln Leu1 5 10 15Phe Ala Val Asp Ser Gly Asn Asp Val Thr
Asp Ile Ala Asp Asp Gly 20 25 30Cys Pro Lys Pro Pro Glu Ile Ala His
Gly Tyr Val Glu His Ser Val 35 40 45Arg Tyr Gln Cys Lys Asn Tyr Tyr
Lys Leu Arg Thr Glu Gly Asp Gly 50 55 60Val Tyr Thr Leu Asn Asp Lys
Lys Gln Trp Ile Asn Lys Ala Val Gly65 70 75 80Asp Lys Leu Pro Glu
Cys Glu Ala Asp Asp Gly Cys Pro Lys Pro Pro 85 90 95Glu Ile Ala His
Gly Tyr Val Glu His Ser Val Arg Tyr Gln Cys Lys 100 105 110Asn Tyr
Tyr Lys Leu Arg Thr Glu Gly Asp Gly Val Tyr Thr Leu Asn 115 120
125Asn Glu Lys Gln Trp Ile Asn Lys Ala Val Gly Asp Lys Leu Pro Glu
130 135 140Cys Glu Ala Val Cys Gly Lys Pro Lys Asn Pro Ala Asn Pro
Val Gln145 150 155 160Arg Ile Leu Gly Gly His Leu Asp Ala Lys Gly
Ser Phe Pro Trp Gln 165 170 175Ala Lys Met Val Ser His His Asn Leu
Thr Thr Gly Ala Thr Leu Ile 180 185 190Asn Glu Gln Trp Leu Leu Thr
Thr Ala Lys Asn Leu Phe Leu Asn His 195 200 205Ser Glu Asn Ala Thr
Ala Lys Asp Ile Ala Pro Thr Leu Thr Leu Tyr 210 215 220Val Gly Lys
Lys Gln Leu Val Glu Ile Glu Lys Val Val Leu His Pro225 230 235
240Asn Tyr Ser Gln Val Asp Ile Gly Leu Ile Lys Leu Lys Gln Lys Val
245 250 255Ser Val Asn Glu Arg Val Met Pro Ile Cys Leu Pro Ser Lys
Asp Tyr 260 265 270Ala Glu Val Gly Arg Val Gly Tyr Val Ser Gly Trp
Gly Arg Asn Ala 275 280 285Asn Phe Lys Phe Thr Asp His Leu Lys Tyr
Val Met Leu Pro Val Ala 290 295 300Asp Gln Asp Gln Cys Ile Arg His
Tyr Glu Gly Ser Thr Val Pro Glu305 310 315 320Lys Lys Thr Pro Lys
Ser Pro Val Gly Val Gln Pro Ile Leu Asn Glu 325 330 335His Thr Phe
Cys Ala Gly Met Ser Lys Tyr Gln Glu Asp Thr Cys Tyr 340 345 350Gly
Asp Ala Gly Ser Ala Phe Ala Val His Asp Leu Glu Glu Asp Thr 355 360
365Trp Tyr Ala Thr Gly Ile Leu Ser Phe Asp Lys Ser Cys Ala Val Ala
370 375 380Glu Tyr Gly Val Tyr Val Lys Val Thr Ser Ile Gln Asp Trp
Val Gln385 390 395 400Lys Thr Ile Ala Glu Asn 405
* * * * *